systems and methods for measuring high-precision analyte

专利摘要:
SYSTEMS AND METHODS FOR HIGH PRECISION ANALYTICAL MEASUREMENT. These are methods for determining an analyte concentration in a sample, and the devices and systems used in conjunction with it, that are provided in this document. In an exemplary embodiment of a method for determining an analyte concentration in a sample, a sample that includes an analyte is provided in a sample that analyzes a device that has a counter electrode and a working electrode. An electrical potential is applied between the electrodes and a first concentration of analyte is determined. A second analyte concentration value is calculated from the first analyte concentration value and corrected for temperature effects, having to fill and capacitance to provide a final analyte concentration value.
公开号:BR112013016911A2
申请号:R112013016911-7
申请日:2010-12-31
公开日:2020-09-24
发明作者:Ronald C. Chatelier；Alastair M. Hodges
申请人:Cilag Gmbh International；
IPC主号:

专利说明:

Invention Patent Descriptive Report for "SYSTEMS AND METHODS FOR HIGH PRECISION ANALYTICAL MEASUREMENT".
FIELD The present invention relates to the system and the method provided here refer to the medical test field, in particular, the detection of the presence and / or concentration of an analyte (s) within a sample (for example, example, physiological fluids including blood).
BACKGROUND Determination of the analyte concentration in physiological fluids (for example, blood or blood products such as plasma) is of increasing importance in today's society. Such assays find use in a variety of applications and configurations, including clinical laboratory testing, home testing, etc., in which the results of such testing play a prominent role in the diagnosis and management of a variety of disease conditions. Analytes of interest include glucose for managing diabetes, cholesterol for monitoring cardiovascular conditions, and the like. In response to this growing importance of analyte detection, a variety of protocols and analyte detection devices have been developed for clinical and residential use. Some of these devices include electrochemical cells, electrochemical sensors, hemoglobin sensors, antioxidant sensors, biosensors, and immunosensors. A common method for assays for determining analyte concentration is based on electrochemistry. In such methods, an aqueous liquid sample is placed in a sample reaction chamber on a sensor, for example, an electrochemical cell consisting of at least two electrodes, that is, a working electrode and a counter electrode, in which the electrodes have an impedance that makes them suitable for amperometric or coulometric measurement. The component to be analyzed is allowed to react with an oxidizable (or reducible) substance in an amount proportional to the analyte concentration. The amount of oxidizable (or reducible) substance present is then estimated electrochemically and refers to the concentration of analyte in the sample.
A blood characteristic that can affect analyte detection is hematocrit.
Hematocrit levels can be widely different among different individuals.
As a non-limiting example, an individual suffering from anemia may have a hematocrit level of approximately 20% while a neonate may have a hematocrit level of approximately 65%. Even samples taken from the same individual over a period of time can have different levels of hematocrit.
Additionally, due to the fact that the high level of hematocrit can also increase blood viscosity, and viscosity can, in turn, affect other parameters associated with analyte detection, the representation of the hematocrit effect in a sample can be important in producing accurate analyte concentration determinations.
One way in which varying levels of hematocrit in a blood sample was represented is by separating the plasma from the blood and then recalculating the concentration of the antigen in relation to the adjusted plasma volume.
The separation was achieved, for example, by performing a centrifugation step.
Other ways in which varying levels of hematocrit in a blood sample were represented include using a mean hematocrit in a calculation or measurement of a hematocrit in a separate step and then calculating the concentration of the antigen in relation to the plasma value .
These methods, however, are believed to be undesirable, at least due to the fact that they involve unwanted sample handling, take additional time and / or lead to substantial errors in final determinations.
In addition, the temperatures in the environments in which samples are analyzed can also have a negative impact on the accuracy of the determination of analyte concentration.
A desirable attribute of all sensor elements is that they have a long shelf life - that is, the perception characteristic of the sensor element does not change significantly between manufacture and use (that is, during storage). However, when stored for long periods of time and / or in non-ideal storage conditions, for example, high temperatures, high humidity, etc., the performance of sensors may degrade. For example, the accuracy of analyte concentration determinations made using such sensors can be reduced. It is an objective for the present invention to overcome or improve these and other disadvantages in the prior art.
SUMMARY Applicants recognized that it would be desirable to develop a way to obtain more accurate analyte concentration measurements across a broad spectrum of donors, analyte concentration levels, hematocrit levels, temperatures and sensor storage conditions with little or no no complementary issues noted previously. Consequently, systems, devices and methods are, in general, provided for determining an accurate concentration of an analyte in a sample. In general, the systems, devices and methods disclosed herein include applying a series of corrections to an optimized analyte concentration measurement to provide an improved precision corrected analyte concentration value. In an exemplary modality, of a method of determining an analyte concentration in a sample, in which the method includes the detection of a sample, including an analyte, introduced in an electrochemical sensor. The electrochemical sensor can include, for example, two electrodes in a separate configuration. In other embodiments, the two electrodes may include a forward orientation. In other modalities, the electrochemical sensor may include two electrodes in an orientation facing the opposite side. In some embodiments, the electrochemical sensor may include a glucose sensor. In other embodiments, the electrochemical sensor may include an immunosensor. In some embodiments, the sample may include blood or whole blood. In some embodiments, the analyte may include C-reactive protein. The method further includes reacting the analyte to cause a physical transformation of the analyte between the two electrodes. For example, the
The analyte can generate an electroactive species that can be measured as a current through the two electrodes. The method also includes measuring current outputs at different intervals to derive a sample load time on the sensor and a capacitance of the sensor with the sample. The method also includes determining a first analyte concentration value from the current outputs; calculating a second analyte concentration value from the current outputs and the first analyte concentration value; correcting the second analyte concentration value for temperature purposes to provide a third analyte concentration value; correction of the third analyte concentration value as a function of the sensor load time to provide a fourth analyte concentration value; and the correction of the fourth analyte concentration value as a function of capacitance to provide a final analyte concentration value. In an exemplary modality, a method of obtaining an increased accuracy of a test strip, in which the method includes providing a batch of test strips, each test strip having two separate electrodes with a reagent disposed between them. As used herein, the term "batch" refers to a plurality of test strips from the same manufacturing cycle which are presumed to have similar characteristics. For example, a batch may contain approximately 500 test strips from a manufacturing batch of approximately
180,000 test strips. The method additionally includes the introduction of a reference sample that contains a reference concentration of an analyte for each batch of test strips. The method also includes the reaction of the analyte to cause a physical transformation of the analyte between the two electrodes; the measurement of current outputs at different intervals to derive a sample load time on the sensor and a capacitance of the sensor with the sample; and determining a first analyte concentration value from the current outputs. The method also includes calculating a second analyte concentration value from the current outputs and the first analyte concentration; correction of the second control value
analyte centering for temperature purposes to provide a third analyte concentration value; correcting the third analyte concentration value as a function of the sensor load time to provide a fourth analyte concentration value; and the correction of the fourth value of 5 analyte concentration as a function of capacitance to provide a final analyte concentration value for each batch of test strips so that at least 95% of the final analyte concentration values of the batch of test strips are within 10% of the reference analyte concentration.
In an exemplary embodiment, of the methods mentioned above, current outputs measured at different intervals may include a first ir current sum and a second useful current sum.
In some embodiments, the distinct intervals over which the first sum of current ir and the second sum of current il are measured can be measured from the time a sample is deposited in the test chamber and may include a first interval of about 3.9 seconds to about 4 seconds and a second interval of about 4.25 seconds to about 5 seconds.
For example, the first sum of current can be expressed by the equation and the second sum of current il can be expressed by the equation.
where i (t) can include the absolute value of the current measured at time t.
In some exemplary modalities of the methods mentioned above, the step of determining the first analyte concentration value may include calculating an G1 analyte concentration with an equation of the form:
where p can be about 0.5246;
a can be about 0.03422; i2 can be an antioxidant corrected current value; and zgr can be about 225. In some exemplary modalities of the methods mentioned above, the step of calculating the second analyte concentration value can include calculating an analyte concentration G2 with an equation of the form:
wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; AFO comprises about 2.88; zgr comprises about 2.25; and k comprises about 0.0000124. In some exemplary modalities of the methods mentioned above, the third analyte concentration value may include a first temperature correction in relation to the second analyte concentration value whenever an ambient temperature is higher than the first temperature threshold and a second temperature correction whenever the ambient temperature is less than or equal to the first temperature threshold.
In some examples that exemplify the methods mentioned above, the correction step of the third analyte concentration value as a function of the sensor load time may include the calculation of a load time correction factor based on the charge.
For example, the charge time correction factor can be about zero when the charge time is less than a first charge time threshold.
For another example, the charge time correction factor can be calculated based on the charge time when the charge time is greater than the first charge time threshold and less than a second charge time threshold. .
For yet another example, the charge time correction factor can include a constant value when the charge time is greater than the second charge time threshold.
In some embodiments, the first charge time threshold can be about 0.2 seconds and the second charge time threshold can be about 0.4 seconds.
In some exemplary modalities of the methods mentioned above, the fourth analyte concentration value may be equal to the third analyte concentration value when the third analyte concentration value is less than an analyte concentration threshold of, for example , about 100 mg / dl.
When the third analyte concentration value is greater than about 100 mg / dl, for example, the fourth analyte concentration value may include a product of the third analyte concentration value, with a deviation from the load time correction factor.
In some exemplary embodiments of the methods mentioned above, the final analyte concentration value can be set to be approximately equal to the fourth analyte concentration value when the fourth analyte concentration value is less than a first concentration threshold.
For example, the first concentration threshold can be about 100 mg / dl.
In additional exemplary modalities of the methods mentioned above, the final analyte concentration value may include a product of a capacitance correction factor and the fourth analyte concentration value when the fourth analyte concentration value is greater than the first concentration threshold.
For example, the capacitance correction factor for the final analyte concentration value can be based on a measured capacitance when the capacitance is less than a first capacitance threshold and the capacitance correction factor can be set to a maximum value when the calculated capacitance correction factor is greater than an established value.
In an exemplary embodiment, of an analyte measuring device, the device may include a housing, a strip port connector mounted on the housing and configured to receive an analyte test strip and a microprocessor arranged in the housing, where the microprocessor is connected to the strip port connectors, a power supply and a memory so that when an analyte test strip is attached to the strip port with the sample deposited in a test strip test chamber , the analyte is forced to react between the two electrodes and to provide one or more of a first G1 analyte concentration estimate based on the output current values measured over different intervals during an analyte reaction, a second 5 estimate of G2 analyte concentration based on the output current values measured over different intervals during an analyte reaction, a corrected analyte concentration value temperature G3 of the second analyte concentration value G2, a sample load time-corrected analyte concentration value of the third analyte concentration G3, and a final corrected concentration value of test strip capacitance G5 of the value of sample loading time corrected analyte concentration G4. In an exemplary embodiment of an analyte measurement system, the system can include a plurality of test strips, where each test strip has at least two separate electrodes in a test chamber and a reagent disposed between them. to receive a sample containing an analyte.
The system can also include an analyte measurement device.
The analyte measurement device may include a strip port that has connectors configured to be compatible with the respective electrodes on each test strip and a microprocessor attached to the strip port.
The microprocessor can be configured to measure current, test strip capacitance and sample charge time with the electrodes of each test strip when the reference sample is deposited in the test chamber of each of the plurality of test strips. test and a final analyte concentration determined based on current, sample load time and test strip capacitance so that the percentage of final analyte concentration values in the test strip batch is within 10% of a reference analyte value above a threshold analyte value.
In some embodiments, the microprocessor can be configured so that when an analyte test strip from the plurality of test strips is coupled to the strip port with the sample deposited on it,
an analyte in the sample reacts between the two electrodes to provide a first estimate of G1 analyte concentration based on measured output current values over different intervals, a second estimate of G2 analyte concentration based on current values Output 5 measured over different intervals, a temperature-corrected analyte concentration value G3 of the second analyte concentration value G2, a sample-time corrected analyte concentration value G4 of the third concentration of analyte and a final corrected concentration value of G5 test strip capacitance from the sample loading time corrected analyte concentration value G4. In an exemplary embodiment, distinct intervals can be measured from the moment a sample is deposited in the test chamber and can include a first interval of about 3.9 seconds to about 4 seconds and a second interval of about 4.25 seconds to about 5 seconds.
Output current values measured over the first and second intervals may include a first sum of currents
current and a second current sum ii, where and where i (t) comprises the absolute value of the current measured at time t.
In some embodiments, the first G1 analyte concentration value may include the derivation of current values with an equation of the form:
where p comprises about 0.5246; a comprises about 0.03422; i2 comprises a current value corrected by antioxidant; and zgr comprises about 2.25. In some embodiments, the second analyte concentration value G2 may include the derivation with an equation of the form:
where p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant corrected current value; AFO comprises about 2.88; zgr comprises about 2.25; and k comprises about 0.0000124. In some modalities, the value of the antioxidant current i2 can
to include an equation of the form: where i (4.1) comprises an absolute value of the current during a third electrical potential; i (1.1) comprises an absolute value of the current during a second electrical potential; and iss comprises a steady-state current In some embodiments, iss can include an equation of the form:
where i (5) comprises an absolute value of the current during a third electrical potential; π comprises a constant; D comprises a diffusion coefficient of an oxide-reduction species, and L comprises a distance between the two electrodes.
In some embodiments, the G3 temperature-corrected analyte concentration value can be corrected by a charge time correction factor based on a charge time.
For example, the charge time correction factor can be about zero when the charge time is less than a first charge time threshold.
For another example, when the charge time is greater than the first charge time threshold and less than a second charge time threshold, the charge time correction factor can be calculated based on the charge time.
For yet another example, when the charge time is greater than the second charge time threshold, the charge time correction factor can include a constant value.
In some embodiments, the first charge time threshold can be about 0.2 seconds and the second charge time threshold can be about 0.4 seconds.
In some embodiments, the temperature-corrected analyte concentration value G3 may include a first temperature correction in relation to the second analyte concentration value G2 whenever an ambient temperature is greater than the first temperature threshold 5 and a second correction temperature whenever the ambient temperature is less than or equal to the first temperature threshold.
In some embodiments, the charge time-corrected analyte concentration value G4 can be the temperature-corrected concentration value G3 when the temperature-corrected concentration value G3 is less than a concentration threshold of, for example, about 100 mg / dl and the G4 loading time corrected concentration value may include a percentage increase in the third analyte concentration value in view of the loading time correction factor when the temperature corrected concentration value G3 is greater than a concentration threshold of, for example, about 100 mg / dl.
In some embodiments, the final corrected concentration value of test strip capacitance G5 can be set to be equal to the fourth analyte concentration value when the sample load time corrected analyte concentration value is less than a first concentration threshold.
For example, the first concentration threshold can be about 100 mg / dl.
In some embodiments, the final corrected concentration value of G5 test strip capacitance may include a product of a capacitance correction factor and the sample load time corrected analyte concentration value G4 when the value analyte concentration corrected for sample loading time G4 is greater than the first concentration threshold.
For example, the capacitance correction factor for the final analyte concentration value G5 can be based on a measured capacitance when the capacitance is less than the first capacitance threshold and the capacitance correction factor can be defined in a maximum value when the calculated capacitance correction factor is greater than an established value.
In another modality of an exemplifying method for the
termination of an analyte concentration in a sample, where the method includes introducing a sample, including an analyte, into an electrochemical sensor.
The method additionally includes the reaction of the analyte to cause a physical transformation of the analyte between the two electrodes and the determination of an analyte concentration.
In another method that exemplifies a method for measuring a corrected analyte concentration in a sample, in which the method includes detecting the presence of the sample in an electrochemical sensor.
The electrochemical sensor can include two electrodes.
The method also includes reacting an analyte to cause a physical transformation of the analyte, determining a first analyte concentration in the sample, and calculating a corrected analyte concentration based on the first analyte concentration and a or more correction factors.
In some embodiments, the step of determining an analyte concentration may include the correction step for one or more of the sample loading times, a physical property of the electrochemical cell, a sample temperature, an electro sensor temperature - chemical and glucose reaction kinetics.
In exemplary modalities, the correction step for glucose reaction kinetics may include calculating a first analyte concentration and calculating a second analyte concentration that depends on the first analyte concentration, so that the magnitude of the correction for glucose reaction kinetics is proportional to the magnitude of the first analyte concentration.
In some embodiments, the physical property of the electrochemical sensor may be related to at least one of the age of the electrochemical sensor and a storage condition of the electrochemical sensor.
For example, the physical property can be a capacitance of the electrochemical cell.
In an exemplary modality, of an electrochemical system, in which the system includes an electrochemical sensor including electrical contacts configured to be compatible with a test meter.
The electrochemical sensor can include a first electrode and a second electrode
in a separate relationship and a reagent.
The test meter may include a processor configured to receive current data from the electrochemical sensor by applying voltages to the test strip.
The test meter can be further configured to determine a corrected analyte concentration based on a calculated analyte concentration and one or more sample loading times, a physical property of the electrochemical sensor, a sample temperature, an electrochemical sensor temperature and the glucose reaction kinetics.
In some embodiments, the test meter may include data storage that contains an analyte concentration threshold and a plurality of thresholds related to one or more sample loading times, a physical property of the electrochemical sensor, a temperature - sample size, electrochemical sensor temperature and glucose reaction kinetics.
In some embodiments, the electrochemical system may include a heating element configured to heat at least a portion of the electrochemical sensor.
In some embodiments, at least one of the electrochemical sensor, the test meter and the processor can be configured to measure the sample temperature.
In some modalities, systems and methods can reduce the variation in analyte concentration determinations from, for example, donor to donor and / or gender to gender.
The method can also reduce interference by urate concentration in determining the analyte concentration.
In some embodiments, the systems and methods of the present invention can achieve an accuracy standard of at least ± 10% for certain analyte concentrations (eg glucose) above an analyte concentration threshold, so that at least minus 95% of a series of analyte concentration assessments produce an analyte concentration value that is accurate within a 10% range of a reference analyte measurement.
In another example, the method can achieve an accuracy standard of at least ± 10 mg / dl for concentrations
analyte concentrations (eg plasma glucose in a whole blood sample) below the analyte concentration threshold, so that at least 95% of a series of analyte concentration assessments yield an analyte concentration value that is accurate within a range of about 5 10 mg / dl of a reference analyte measurement. For example, the analyte concentration threshold can be about 75 mg / dl of plasma glucose in a whole blood sample. For another example, the standard of precision can be achieved over a series of more than about 5,000 analyte concentration assessments. For yet another example, the standard of precision can be achieved over a series of more than about 18,000 analyte concentration assessments. These and other modalities, resources and advantages become evident to the person skilled in the art when taken with reference to the more detailed description below of several exemplary modalities of the invention in conjunction with the attached drawings that are, first described soon.
BRIEF DESCRIPTION OF THE DRAWINGS Various features of the present description are presented with particularity in the appended claims. A better understanding of such resources can be obtained by reference to the detailed description below which presents illustrative non-limiting modalities and the accompanying drawings in which: Figure 1A illustrates a perspective view of an exemplary test strip; Figure 1B shows an exploded perspective view of the test strip of Figure 1A; Figure 1C shows a perspective view of a distal portion of the test strip of Figure 1A; Figure 2 shows a bottom plan view of the test strip of Figure 1A; Figure 3 illustrates a side plan view of the test strip of the
Figure 1A; Figure 4A illustrates a top plan view of the test strip of Figure 1A; Figure 4B shows a partial side view of the distal portion of the test strip consistent with the arrows 4B-4B of Figure 4A; Figure 5A illustrates a simplified schematic showing a test meter that electrically interfaces with the test strip contact blocks; Figure 5B illustrates an exemplary analyte measurement system including a test strip and an analyte test meter; Figure 5C illustrates a simplified schematic view of an exemplary circuit board for the meter of Figure 5B; Figure 6 illustrates an exploded view of an immunosensor e-exemplifying embodiment; Figure 7A illustrates a test voltage waveform in which the test meter applies a plurality of test voltages over prescribed time intervals; Figure 7B illustrates a test current transient generated with the test voltage waveform of Figure 6; Figure 8A illustrates a test voltage waveform in which the test meter applies a plurality of test voltages at opposite polarity for prescribed time intervals as compared to Figure 7A; Figure 8B illustrates a test current transient generated with the test voltages of Figure 8A; Figure 9 is a graph showing an average bias in blood samples from male and female donors using the first algorithm and a second algorithm disclosed here; Figure 10 illustrates a bias plot of a reference glucose measurement versus the reference glucose measurement for each member of a data set including approximately 18,970 glucose assays;
Figure 11 illustrates a bias plot of a reference glycoside measurement against the percentage of hematocrit for each member of a data set including approximately 18,970 glycosis assays; 5 Figure 12 illustrates a bias plot of a reference glycoside measurement versus temperature measurement for each member of a data set including approximately 18,970 glucose assays; Figure 13 illustrates a bias plot of a reference glycoside measurement against test strip storage time for members of a data set in which the glucose concentration was less than about 75 mg / dl; Figure 14 illustrates a bias plot of a reference glycoside measurement against test strip storage time for members of a data set in which the glucose concentration was greater than about 75 mg / dl.
DETAILED DESCRIPTION The following detailed description should be read with reference to the drawings, in which the same elements in different drawings are numbered identically. The drawings, which are not necessarily scaled, show selected modalities and are not intended to limit the scope of the invention. The detailed description illustrates, by way of example, not by way of limitation, the principles of the invention. As used herein, the terms "about" or "approximately" for which numeric values or ranges indicate an adequate dimensional tolerance that allows part or set of components to function for their intended purpose as described herein. In addition, as used herein, the terms "patient", "host", "user" and "individual" refer to any human or animal individual and are not intended to limit systems or methods for human use, although the use of the invention in question in a human patient represents a preferred modality. Certain exemplifying modalities will be described to provide
provide a general understanding of the principles of structure, function, manufacture and use of the systems and methods disclosed herein.
One or more examples of these modalities are illustrated in the accompanying drawings.
Those skilled in the art will understand that the systems and methods specifically described here and illustrated in the accompanying drawings are exemplary non-limiting modalities and that the scope of the present description is defined only by the claims.
The resources illustrated or described in connection with an exemplary modality can be combined with the resources of other modalities.
Such modifications and variations are intended to be included within the scope of this description.
As will be discussed in more detail below, the systems and methods disclosed include the determination of a first analyte concentration value; calculating a second analyte concentration value from the first analyte concentration value; correcting the second analyte concentration value for temperature purposes in order to provide a third analyte concentration value; correction of the third analyte concentration value as a function of the sensor charge time in order to provide a fourth analyte concentration value; and correcting the fourth analyte concentration value as a function of capacitance in order to provide a final analyte concentration value.
The systems and methods currently disclosed are suitable for use in determining a wide variety of analytes in a wide variety of samples, and are particularly suitable for use in determining analytes in whole blood, plasma, serum, interstitial fluid or derivatives of the same.
In an exemplary modality, a glucose test system based on a thin layer cell model with opposite electrodes and crew electrochemical detection that is fast (for example, about 5 seconds or less analysis time), requires a small sample (for example, about 0.4 µl, or less), and can provide improved reliability and accuracy of blood glucose measurements.
In the reaction cell to analyze the analyte, the glucose in the sample can be oxidized to gluconolactone with the use of glucose dehydrogenase and a
Electrochemically active additive can be used to transport electrons from the enzyme to a working electrode.
More particularly, a reagent layer that covers at least one of the electrodes in the reaction cell can include glucose dehydrogenase (GDH) based on quinone pyrroloquinoline (PQQ) cofactor and ferricyanide.
In another embodiment, the GDH enzyme based on the PQQ cofactor can be replaced by the GDH enzyme based on the flavin adenine dinucleotide (FAD) cofactor. When blood or control solution is dosed into the reaction chamber, glucose is oxidized by G-DH (ox) and, in the process, converts GDH (ox) to GDH (red), as shown in chemical transformation T. 1 below.
Note that GDH (ox) refers to the oxidized state of GDH, and GDH (red) refers to the reduced state of GDH.
T.1 D-Glucose + GDH (ox) -> Gluconic acid + GDH (red) A potentiostat can be used to apply a potential manned waveform to working electrodes and counter electrodes, resulting in test current transients used to calculate the concentration of glucose.
In addition, additional information acquired from the test current transients can be used to discriminate between sample matrices and correct variability in blood samples due to hematocrit, temperature variation, electrochemically active components, and to identify possible errors of system.
The methods in question can be used, in principle, with any type of electrochemical cell sensor that has separate first and second electrodes and a reagent layer.
For example, an electrochemical cell sensor may be in the form of a test strip.
In one aspect, the test strip can include two opposing electrodes separated by a thin spacer for defining a sample receiving chamber or zone in which a reagent layer is located.
The applicant notes that other types of test strips, including, for example, test strips with coplanar electrodes, can also be used with the systems and methods described here.
The devices used with the systems and methods described herein typically include at least one working electrode and a counter electrode between which an electrical potential can be applied.
The sample analysis device can, in general, be associated with a component for the application of the electrical potential between the electrodes, such as a meter.
The applicant notes that a variety of test meters can be used with the systems and methods described herein.
However, in one embodiment, the test meter includes at least one processor, which may include one or more control units configured to perform calculations that have the ability to calculate a correction factor in view of at least a measured or calculated parameter as well as configured for classification and / or data storage.
The microprocessor can be in the form of a mixed signal microprocessor (MSP) such as Texas Instruments MSP 430. The TI-MSP 430 can also be configured to perform a portion of the potentiostat function and the current measurement.
In addition, the MSP 430 can also include volatile and non-volatile memory.
In another embodiment, many of the electronic components can be integrated into the microcontroller in the form of an application-specific integrated circuit.
Electrochemical Cells Figures 1A-4B show several views of an xemplifier test strip 62 suitable for use with the methods described herein.
As shown, test strip 62 may include an elongated body extending from a distal end 80 to a proximal end 82, and which has side edges 56, 58. The distal portion of body 59 may include a reaction chamber sample 61 which has multiple electrodes 64, 66 and a reagent 72, while the proximal portion of the test strip body 59 may include features configured to communicate electrically with a test meter.
During operation, the physiological fluid or a control solution can be delivered to the sample reaction chamber 61 for electrochemical analysis.
As used here, the term "proximal" indicates that a reference structure is closer to the test meter and the term "distal" indicates that a reference structure is further away from the test meter.
In the illustrative embodiment, the test strip 62 can include a first electrode layer 66 and a second electrode layer 64, with a spacer layer 60 positioned between them.
The first electrode layer 66 can provide a first electrode 166 and a first connection follow-up 76 to electrically connect the first 5 electrode 166 to a first electrical contact 67. Similarly, the second electrode layer 64 can provide a second electrode 164 and a second connection monitoring 78 to electrically connect the second electrode 164 to a second electrical contact 63. In one embodiment, the sample reaction chamber 61 is defined by the first electrode 166, the second electrode 164 and a spacer 60 as shown in Figures 1A-4B.
Specifically, the first electrode 166 and the second electrode 164 define, respectively, the lower and upper part of the sample reaction chamber 61. A cutout area 68 of the spacer 60 can define the side walls of the sample reaction chamber 61 In one aspect, the sample reaction chamber 61 may additionally include numerous ports 70 that provide a sample inlet and / or a vent.
For example, one port can provide a fluid sample ticket and the other port can act as a breather.
The sample reaction chamber 61 can have a small volume.
For example, the volume can be in the range of about 0.1 microliter to about 5 microliters, preferably about 0.2 microliter to about 3 microliters, and more preferably, about 0.3 microliter to about 1 microliter.
As will be understood by the person skilled in the art, the sample reaction chamber 61 can have several other volumes.
In order to provide the small volume of sample volume, cutout 68 may have an area ranging from about 0.01 cm2 to about 0.2 cm2, preferably about 0.02 cm2 to about 0.15 cm2, and more preferably about 0.03 cm2 to about 0.08 cm2. Similarly, one skilled in the art will understand that the volume cutout 68 may have several other areas.
In addition, the first and second electrodes 166, 164 can be spaced in the range of about 1 micron to about 500 microns, preferably in the range of about 10 microns to about 400 microns, and with more preferably in the range of about 40 microns to about 200 microns.
In other modalities, this range can vary among several other values.
Spacing close to the electrodes can also allow redox cycling to occur, in which the oxidized mediator generated in the first electrode 166 can diffuse to the second 5 electrode 164 to become reduced, and subsequently diffuse in turns to the first electrode 166 to become oxidized again.
At the proximal end of the test strip body 59, a first electrical contact 67 can be used to establish an electrical connection with a test meter.
A second electrical contact 63 can be accessed by the test meter through a U-shaped notch 65 as illustrated in Figure 2. Applicant notes that test strip 62 may include a variety of alternative electrical contacts configured to electrically connect to a test meter.
For example, U.S. Patent No. 6,379,513, all of which is incorporated herein by reference, discloses an electrochemical cell connection means.
In one embodiment, the first electrode layer 66 and / or the second electrode layer 64 can be a conductive material formed from materials such as gold, palladium, carbon, silver, platinum, tin oxide, iridium, indium, and combinations of them (for example, tin oxide doped with indium). In addition, electrodes can be formed by placing a conductive material on an insulating sheet (not shown) through various processes such as, for example, an ionic bombardment process, non-electrical catalytic deposition or screen printing .
In an exemplary embodiment, the second electrode layer 64 can be an ionically bombarded gold electrode and the first electrode layer 66 can be an ionically bombarded palladium electrode.
Suitable materials that can be employed as the spacing layer 60 include various insulating materials, such as plastics (eg PET, PETG, polyimide, polycarbonate, polystyrene), silicon, ceramic, glass, adhesives , and combinations thereof.
A reagent layer 72 can be disposed inside the sample reaction chamber 61 using a process such as extrusion coating, dispensing from the end of a tube, inkjet and screen printing.
Such processes are described, for example, in the following U.S. Patents: 6,749,887; 6,869,411; 6,676,995; and 6,830,934, the total of 5 each of these references is hereby incorporated by reference.
In one embodiment, the reagent layer 72 can include at least one mediator and one enzyme, and can be deposited on the first electrode 166. Various mediators and / or enzymes are within the spirit and scope of the present description.
For example, suitable mediators include ferricate, ferrocene, ferrocene derivatives, bipyridyl osmium complexes, and quinone derivatives.
Examples of suitable enzymes include glucose oxidize, glucose dehydrogenase (GDH) based on pyrroloquinoline quinone cofactor (PQQ), GDH based on nicotinamide adenine dinucleotide cofactor, and FAD based GDH [ECI1.99.10] . An exemplary reagent formulation, which would be suitable for the manufacture of reagent layer 72, is described in Pending Order No. US 10 / 242,951, entitled, "Method of Manufacturing a Sterilized and Calibrated Biosensor-Based Medical Device", published as Published Patent Application In US 2004/0120848, the entire patent is incorporated herein by reference.
The first electrode 166 or the second electrode 164 can function as a working electrode that oxidizes or reduces a limiting amount of mediator depending on the polarity of the applied test potential of the test meter.
For example, if the current limiting species is a reduced mediator, this can be oxidized at the first electrode 166 as long as a sufficiently positive potential is applied in relation to the second electrode 164. In such a situation, the first electrode 166 performs the function of the working electrode and the second electrode 164 performs the function of a counter / reference electrode.
It should be noted that, except where otherwise stated, for test strip 62, all potentials applied by test meter 100 will now be determined with respect to the second electrode 164. Similarly, if a sufficiently negative potential is applied in relation to the second electrode 164, then the reduced mediator can be oxidized on the second electrode 164. In such a situation, the second electrode 164 can perform the function of the working electrode and the first electrode 166 can perform the function of the counter / reference electrode. 5 Initially, the method currently disclosed may include introducing a quantity of the fluid sample of interest into test strip 62, which includes the first electrode 166, the second electrode 164 and a reagent layer 72. The sample fluid can be whole blood or a derivative or fraction thereof, or a control solution.
The fluid sample, for example, blood, can be dosed in the sample reaction chamber 61 through port 70. In one aspect, port 70 and / or sample reaction chamber 61 can be configured so that the action capillary make the fluid sample load the sample reaction chamber 61. Figure 5 A provides a simplified schematic of a test meter 100 that interfaces with a first electrical contact 67 and a second electrical contact 63, which are in electrical communication with the first electrode 166 and the second electrode 164, respectively, of test strip 62. Test meter 100 can be configured to electrically connect to the first electrode 166 and the second electrode 164 via a first electrical contact 67 and a second electrical contact 63, respectively (as shown in Figures 2 and 5A). As will be understood by the person skilled in the art, a variety of test meters can be used with the method described here.
However, in one embodiment, the test meter includes at least one processor, which can include one or more control units configured to perform calculations that have the ability to calculate a correction factor in view of at least one measured parameter correlated to a physical property of the electrochemical cell, as well as configured for classification and / or data storage.
The microprocessor can be in the form of a mixed signal microprocessor (MSP) such as Texas Instruments MSP 430. The TI-MSP 430 can also be configured to perform a portion of the potentiostat function and the current measurement. THE-
in addition, the MSP 430 can also include volatile and non-volatile memory.
In another embodiment, many of the electronic components can be integrated into the microcontroller in the form of an application-specific integrated circuit. 5 As shown in Figure 5A, an electrical contact 67 can include two forks 67a, 67b.
In an exemplary embodiment, the test meter 100 connects separately to the forks 67a, 67b, so that when the test meter 100 interfaces with a test strip 62, a circuit is closed.
Test meter 100 can measure resistance or electrical continuity between forks 67a, 67b to determine whether test strip 62 is electrically connected to test meter 100. The applicant notes that test meter 100 can use a variety of sensors and circuits to determine when test strip 62 is properly positioned in relation to test meter 100. In one embodiment, a circuit arranged on test meter 100 can apply a test potential and / or a current between the first electrical contact 67 and the second electrical contact 63. Once test meter 100 recognizes that strip 62 has been inserted, test meter 100 turns on and initiates a fluid detection mode.
In one embodiment, the fluid detection mode causes test meter 100 to apply a constant current of about 1 microampere between the first electrode 166 and the second electrode 164. Due to the fact that the test strip 62 is initially dry, the test meter 100 measures a maximum voltage, which is limited by the hardware inside the test meter 100. However, once a user doses a sample of fluid at inlet 70, this causes the chamber to - sample reaction area 61 is loaded.
When the fluid sample points through the gap between the first electrode 166 and the second electrode 164, test meter 100 will measure a decrease in the measured voltage (for example, as described in US Patent 6,193,873, the all of it is incorporated by reference), which is below a predetermined threshold causing the test meter 100 to automatically start the glucose test.
It should be noted that the measured voltage can decrease below a predetermined threshold when only a fraction of the sample reaction chamber 61 has been loaded.
An automatic recognition method that a fluid has been applied does not necessarily indicate that the sample reaction chamber 5 has been fully charged, but it can only confirm the presence of some amount of fluid in the sample reaction chamber 61. Since test meter 100 determines that a fluid has been applied to test strip 62, a small, non-zero amount of time may still be needed to allow the fluid to fully load sample reaction chamber 61. Figure 5B illustrates a diabetes management system that includes a diabetes 10 data management unit and a biosensor in the form of a glucose test strip42. Note that the diabetes data management unit (DMU) can be called an analyte measurement and management unit, a glucose meter, a meter and an analyte measurement device.
In a fashion, the DMU can be combined with an insulin delivery device, an additional analyte test device and a drug delivery device.
The DMU can be connected to a computer or server using a cable or suitable wireless technology, such as GSM, CDMA, BlueTooth, WiFi and the like.
Again, referring to Figure 5B, the DMU 10 can include a housing 11, user interface buttons (16, 18 and 20), a display 14 and a strip port entry 22. The user interface buttons ( 16, 18 and 20) can be configured to allow data entry, menu navigation, and command execution.
The user interface button 18 can be in the form of a switch with bidirectional elbow action.
The data may include values representative of the analyte concentration, and / or information, which are related to an individual's daily lifestyle.
The information, which is related to the daily lifestyle, may include food intake, medication use, the occurrence of complete health tests (check-up), and general health condition and exercise levels.
exercise of an individual.
The electronic components of the DMU 10 can be arranged on a circuit board 34 that is inside the housing 11. Figure 5C illustrates (in a simplified schematic form) the electronic components arranged on an upper surface of the circuit board 34. In the top surface, electronic components may include a strip port input 308, a microcontroller 38, a non-volatile fast memory 306, a data port 13, a real-time clock 42 and a plurality of operational amplifiers ( 46 to 49). On the bottom surface, electronic components can include a plurality of analog switches, a backlight unit and a programmable read-only memory that can be electrically erasable (EEPROM, not shown). Microcontroller 38 can be electrically connected to strip port input 308, non-volatile fast memory 306, data port 13, real time clock 42, the plurality of operational amplifiers (46 to 49), the plurality analog switches, the rear light unit and the EEPROM.
Again, referring to Figure 5C, the plurality of operational amplifiers can include gain stage operational amplifiers (46 and 47), a transimpedance operational amplifier 48, and a bias unit operational amplifier 49. The plurality of Operational amplifiers can be configured to provide a portion of the potentiostat function and the current measurement function.
The potentiostat function can refer to the application of a test voltage between at least two electrodes on a test strip.
The current function can refer to the measurement of a test current that results from the applied test voltage.
Current measurement can be performed with a current-to-voltage converter.
Microcontroller 38 may be in the form of a mixed signal microprocessor (MSP), such as Texas Instruments MSP 430. The MSP 430 can also be configured to perform a portion of the potentiostat function and the measurement function due.
In addition, the MSP 430 can also include volatile and non-volatile memory.
In another embodiment, many of the electronic components can be integrated into the microcontroller in the form of an application-specific integrated circuit (ASIC). The strip port connector 308 can be located close to the strip port entrance 22 and configured to form an electrical connection 5 with the test strip.
The display 14 may be in the form of a liquid crystal display to report measured glucose levels, and to facilitate the entry of lifestyle-related information.
The display 14 can optionally include a back light.
The data port 13 can accept a suitable connector attached to a connecting conductor, thus allowing the glucose meter 10 to be connected to an external device such as a personal computer.
Data port 13 can be any port that allows data transmission, for example, a serial port, USB, or a parallel port.
The real time clock 42 can be configured to maintain the current time related to the geographic region in which the user is located and also to perform time measurement.
The real time clock 42 may include a clock circuit 45, a crystal 44, and a supercapacitor 43. The DMU can be configured to be electrically connected to a power source, such as a battery.
Supercapacitor 43 can be configured to provide power for an extended period of time to power real time clock 42 in the event of a power supply interruption.
In this way, when a battery discharges or is replaced, the real time clock does not need to be reset by the user to an appropriate time.
The use of the real-time clock 42 with the super-capacitor 43 can reduce the risk of a user resetting the real-time clock 42 incorrectly.
Another exemplary embodiment of a sample analysis device for use in conjunction with at least part of the methods disclosed herein, an immunosensor 110, is illustrated in Figure 6 and is described in US Patent Application Serial No. 12 / 570,268 of Chatelier et al., Entitled "Adhesive Compositions for Use in an Immunosensor" and deposited on September 30, 2009, the contents of which are hereby incorporated by reference in their entirety.
A plurality of chambers can be formed inside the immunosensor, including a loading chamber, through which a sample can be introduced into the immunosensor, a reaction chamber, through which a sample can react with one or more desired materials 5 , and a detection chamber, through which a concentration of a particular component of the sample can be determined.
These chambers can be formed in at least a portion of a first electrode, a second electrode and an immunosensor separator.
The immuno-sensor may also include a vent hole to allow air to enter and escape the immunosensor as desired, and first and second sealing components to selectively seal the first and second sides of the breather first. .
The first sealing component can also form a wall in the loading chamber.
As illustrated, immunosensor 110 includes a first electrode 112 that has two liquid reagents 130, 132 deposited thereon.
The first electrode 112 can be formed using any number of techniques used to form electrodes, but, in one mode, a sheet of polyethylene teraftalate (PET) that is charged with barium sulphate is coated by bombardment. ionic with gold.
The PET slide can also be charged with titanium dioxide.
Other non-limiting examples of electrode formation are disclosed in US Patent No. 6,521,110 to Hodges et al., Entitled "Electrochemical cell" and deposited on November 10, 2000, the contents of which are incorporated here reference title in its entirety.
Likewise, liquid reagents 130, 132 can have a number of different compositions.
In one embodiment, the first liquid reagent 130 includes an antibody conjugated to an enzyme, such as GDH-PQQ, in a buffer containing sucrose, as well as a poloxamer, such as Pluronics ® block copolymers, an anticoagulant, such as citraconate, and calcium ions.
In one embodiment, the second liquid reagent 132 includes a mixture of ferricyanide, glucose, and a second mediator, such as phenazine ethosulfate, in an acidic buffer, such as a diluted citraconic acid solution.
The first and second liquid reagents 130, 132 can be dried on the first electrode 112. Numerous techniques can be used to dry reagents 130, 132, but, in one embodiment, after deposition of reagents 130, 132 on first electrode 112, one or more infrared dryers can be applied to reagents 130, 132. One or more air dryers can also be used, for example, subsequent to infrared dryers.
References to a first reagent and a first liquid reagent and a second reagent and a second liquid reagent here are used in a subject to change and are not necessarily an indication that the reagents are in liquid or dry form in a instant data for a particular modality.
In addition, some of the components associated with the first and second liquid reagents can be used in a changeable manner and / or with the first and second liquid reagents as desired.
As a non-limiting example, an anticoagulant can be associated with one or both of the first liquid reagent 130 and the second liquid reagent 132. An electrically insulating line can be formed in the gold coated by ion bombardment between the reagents 130, 132 so that an edge of reagent 132 is very close to, or touches, the line.
The line can be applied with the use of laser ablation or with a sharp metallic edge.
In an exemplary embodiment, the line can be applied before reagents 130, 132 are deposited on the electrode.
The line can be designed to electrically isolate the section of the first electrode 112 under the detection chamber from the section that will be under the reaction chamber.
This can provide a more satisfactory definition of an area of the working electrode during the electrochemical test.
Immunosensor 110 may also include a second electrode 114 that has one or more magnetic microspheres 134 containing surface bound antigens in it.
The antigens can be configured to react with the antibody disposed on the first electrode 112 and the sample inside a reaction chamber 118, as described in more detail below.
The person skilled in the art will recognize that the components arranged in the first
The electrode 112 and the second electrode 114 may be subject to change.
In this way, the first electrode 112 can include one or more magnetic microspheres 134 and the second electrode 114 can include two liquid reagents 130, 132 deposited thereon.
In addition, although in the illustrated fashion, electrode length 112 forms the entire length of the body of the immunosensor 110, in other embodiments, the electrode may be just a portion of an immunosensor layer that serves as the first or second electrodes or multiple electrodes can be arranged in a single layer of an immunosensor.
Additionally, due to the fact that the voltage applied to the immunosensor can be inverted and / or alternated, each of the first and second electrodes can serve as the working electrode and the reference or counter / reference electrode in different stages. .
For purposes of description purposes, in the present application, the first electrode is considered the working electrode and the second electrode is the counter or counter / reference electrode.
A separator 116 disposed between the first and second electrodes 112, 114 can have a variety of shapes and sizes, but, in general, is configured to desirably engage the first and second electrodes 112, 114 to form the immunosensor 110. In an e-exemplifying embodiment, the separator 116 includes adhesive on both sides.
Separator 116 may additionally include a non-stick liner on each side on both sides of separator 116 in order to facilitate the manufacturing process.
Each nonstick liner is removed before the separator is connected to each electrode.
The separator 116 can be cut so that it forms at least two cavities.
A first cavity can be formed to serve as a reaction chamber 118 and a second cavity can be formed to serve as a detection chamber 120. In one embodiment, separator 116 can be cut in half (kiss-cut) from so that reaction chamber 118 is aligned to electrodes 112, 114 to allow an antigen and antibody reaction to it while detection chamber 120 is aligned to electrodes 112, 114 to allow electrochemical determination of ferrocyanide in it.
In one embodiment, the separator 116 can be placed on the first electrode 112 in a way that allows the magnetic microspheres 134 of the second electrode 114 and the first reagent 130 of the first electrode 112 to be at least partially disposed in the reaction chamber 5 118 and that the combination of ferricyanide and glucose from the second reagent 132 from the first electrode 112 is at least partially arranged in the detection chamber 120. It may be advantageous to include an anticoagulant in each of the first and second liquid reagents 130, 132 so that an anticoagulant be associated with each one of the detection and reaction chambers 118, 120. In some embodiments, the combination of one of the first and second electrodes 112, 114 and the separator 116 can be laminated together to form a bilaminate, although in other embodiments the combination of each of the first electrode 112, the second electrode 114 and the separator 116 can be laminated together to form a trilaminate. Alternatively, additional layers can also be added. A charge chamber 122 can be formed by drilling a hole in one of the first and second electrodes 112, 114 and separator 116. In the illustrated embodiment, the charge chamber is formed by drilling a hole in the first electrode 112 and in the separator 116 so that the hole in the first electrode 112 overlaps the reaction chamber 118. As shown, the loading chamber 122 can be separated by a distance from the detection chamber 120. Such a configuration allows a sample between the immunosensor 110 through the loading chamber 122 and flowing into the reaction chamber 118 is reacted, for example, with the first liquid reagent 130 that includes the antibody conjugated to an enzyme in a buffer on the first electrode 112 and the magnetic microspheres 134 deposited on the second electrode 114, without entering the detection chamber
120. Once the sample has been reacted, it can then flow into the detection chamber 120 to undergo a chemical or physical transformation with the second liquid reagent 132, for example, the ferricyanide mixture, glucose, and the second mediator in an acidic buffer.
A breather 124 can be formed by drilling a hole through each of the two electrodes 112, 114 and the separator 116 so that breather 124 extends through the entire immunosensor 110. The orifice can be formed appropriate, such as, for example, drilled with the aid of a drill or drilled in numerous different locations, but in an exemplary modality, it can overlap a region of the detection chamber 120 that is separate from the reaction 118. Breather 124 can be sealed in a number of different ways.
In the illustrated embodiment, a first sealing component 140 is located on the first electrode 112 to seal a first side of the vent 124 and a second sealing component 142 is located on the second electrode 114 to seal a second side of the vent 124. The components seals can be manufactured from and / or include any number of materials.
As a non-limiting example, either or both of the sealing components can be hydrophilic adhesive tape or Scotch® tape. The adhesive sides of the sealing components can face immunosensor 110. As shown, not only can the first sealing component 140 form a seal for breather 124, but it can also form a wall for the chamber load 122 so that the sample can be confined therein.
The properties incorporated in the adhesive side of the first sealing component 140 can be associated with the loading chamber 122. For example, if the first sealing component 140 includes properties that make it hydrophilic and / or water-soluble, the loading chamber can remain moist when the sample is placed in it.
In addition, sealing components 140, 142 can be selectively associated and disassociated with immunosensor 110 in order to provide vent and / or sealing for immunosensor 110 and the components disposed thereon as desired.
In general, adhesives can be used in the construction of the immensor.
Non-limiting examples of ways in which adhesives can be incorporated into immunosensors and other sample analysis devices of the present description can be found in US Patent Application Serial No. 12 / 570.268 by Chatelier et al., Entitled " Adhesive Compositions for Use in an Immunosensor "and deposited on September 30, 2009, the content of which is already incorporated by reference in its entirety.
Although the present description discusses a variety of different immunosensor-related modalities, other immunosensor modalities can also be used with the methods of the present description.
Non-limiting examples of such modalities include those described in US Patent Application Publication No. 2003/0180814 by Hodges et al., Entitled "Direct Immunosensor Assay" and filed on March 21, 2002, in US Patent Application Publication 2004 / 0203137 by Hodges et al., Entitled "Immunosensor" and filed on April 22, 2004, in Patent Application Publication No. US 2006/0134713 by Rylatt et al., Entitled "Biosensor Apparatus and Methods of Use" and declared on November 21, 2005, and in US Patent Application Serial No. 12 / 563,091, which claims priority for each of US Patent Application Publication Nos. 2003/0180814 and 2004/0203137, each is here incorporated as a reference in its entirety.
In one embodiment, the immunosensor 110 can be configured to be placed on a meter meter which is configured, for example, through a suitable circuit, to apply a potential to electrodes 112, 114 and measure a current that results from the application of the potential.
In one embodiment, the immunosensor includes one or more tabs 117 to engage a meter.
Other features can also be used to attach the immunosensor 110 to a meter.
The meter can include a number of different features.
For example, the meter may include a magnet that is configured to hold certain components of the immunosensor 110 in one chamber while other components flow into the other.
In an exemplifying embodiment, the magnet of the meter is located so that, by placing the immunosensor 110 on the meter, the magnet is placed below the reaction chamber 118. This can allow the magnet to assist in the retention of any magnetic microspheres 134 , and, more particularly, any antibody and enzyme conjugate that is attached to microspheres 134, flow into the detection chamber 120. An alternative feature of the meter includes a heating element.
A heating element can help to accelerate the rate of reaction and helps the sample to flow through the immunosensor 110 in a desired way by reducing the viscosity.
A heating element can also allow one or more chambers and / or a sample disposed therein to be heated to a predetermined temperature.
Heating to a predetermined temperature can help provide accuracy, for example, by decreasing or removing the effects of temperature changes while reactions occur.
In addition, a drilling instrument can also be associated with the meter.
The drilling instrument can be configured to pierce at least one of the first and second sealing components at a desired time so that air can flow out of the breather orifice and liquid can flow from the reaction chamber to the chamber detection.
Immunosensor 110 and test strip 62 can also be configured to be associated with a control unit.
The control unit can be configured to perform a variety of functions.
In an exemplary mode, the control unit has the ability to measure a sample charge time when it is introduced into the device.
In another embodiment, the control unit can be configured to determine a hematocrit value for a blood sample.
In yet another embodiment, the control unit can be configured to calculate an analyte concentration in the sample in view of the loading time.
In reality, the control unit can include a number of different features, depending, at least in part, on the desired functionality and the method by which the system is designed to measure the charging time.
The control unit can also measure other aspects of the system.
As a non-limiting example, the control unit can be configured to measure a temperature in one or more chambers of the immuno-sensor or the test strip.
It can also be configured to measure a sample temperature, a sample color, a capacitance of the immunosensor i-5 or test strip, or a variety of other characteristics and / or properties of the sample and / or the system.
As an additional non-limiting example, the control unit can be configured to communicate the results of the charge time determination, the results of the capacitance measurement, the results of the analyte concentration determination and / or the hematocrit measurement out of the equipment.
This can be done in a number of ways.
In one embodiment, the control unit can be physically connected (hardwired) to a microprocessor and / or a display device.
In another embodiment, the control unit can be configured to transmit data from the control unit wirelessly to a microprocessor and / or a display device.
Other system components can also be configured to make such measurements.
For example, the immunosensor or the meter can be configured to measure a temperature in one or more chambers of the immunosensor or the test strip, measure or infer the temperature of a sample, or measure, determine or infer a variety of other characteristics and / or properties of the sample and / or the system.
Furthermore, the person skilled in the art will recognize that these features of a control unit can be exchanged and combined selectively in a single control unit.
For example, a control unit can determine a charging time, a capacitance and measure a temperature in a chamber.
In other embodiments, multiple control units can be used together to perform various functions, based at least in part, on the settings of the various control units and the desired functions to be performed.
Analyte Concentration Test In operation, for one modality, since test meter 100 determined that a fluid should be introduced (for example, metered)
on test strip 62, a test meter 100 can perform an analytical test by applying a plurality of test potentials to test strip 62 at prescribed intervals as shown in Figure 7A.
An analyte test time interval tG represents an amount of time 5 to perform the analyte test (but not necessarily all calculations associated with the analyte test) where the analyte test time interval tG can include a first test potential E1 for a first time interval of test potential t1, a second test potential of E2 for a second time interval of test potential t2, and a third test potential E3 for a third time interval of potential t3 test In addition, as shown in Figure 7A, the second test potential time interval t2 may include a constant test voltage component (CD) and an alternating alternating test voltage (AC) component, or oscillating.
The overlapping alternating test voltage component can be applied for a time interval indicated by tcap.
The glucose test time interval tG can be in the range, for example, from about 1 second to about 5 seconds.
As discussed above, either the first electrode 166 or the second electrode 164 can function as the working electrode that oxidizes or reduces a limiting amount of mediator depending on the polarity of the applied test potential of the test meter.
It should be noted that, except where otherwise stated, all potentials applied by test meter 100 will now be determined in relation to second electrode 164. However, the applicant notes that the test potentials applied by test meter 100 can also be established in relation to the first electrode 166, in which case the polarity of the test potentials and measured currents discussed below could be reversed.
The plurality of test current values measured during the first, second and third test potential time intervals can be carried out at a frequency in the range of about 1 measurement for approximately 1 nanosecond to about a measurement for approximately 100 milliseconds.
The applicant notes that the names
"first", "second" and "third" nations are chosen for convenience and do not necessarily reflect the order in which the test potentials are applied.
For example, a modality may have a potential waveform where the third test voltage can be applied before the first and second test voltages are applied.
Although a modality that uses three test voltages in series is described, the applicant notes that the analyte test can include different numbers of test voltages and open circuit.
The applicant notes that the analyte test time interval can include any number of open circuit potential time intervals.
For example, the analyte test time interval could include only two test potential time intervals and / or open circuit potential time intervals before and / or after one or more test potential time intervals. .
In another example, the analyte test could include an open circuit for a first time interval, a second test voltage for a second time interval and a third test voltage for a third time interval.
As shown in Figure 7A, test meter 100 can apply a first test potential E1 (for example, about -20 mV as shown in Figure 7A) for a first time interval of test potential t1 ( for example, in the range of about 0 to about 1 second). The first time interval of test potential t1 can be in the range of about 0.1 second to about 3 seconds, and preferably in the range of about 0.2 second to about 2 seconds, and, with maximum preference, in the range of about 0.3 seconds to about 1 second from an initialization point of zero (0) seconds in Figure 7A.
The first time interval of test potential t1 can be long enough so that the sample reaction chamber 61 can be loaded completely with the sample and also so that the reagent layer 72 can dissolve or solvate at least partially.
In other embodiments, the first t1 test potential time interval can include any other desired time ranges.
In one embodiment, test meter 100 can apply a first test potential E1 between the electrodes for a duration between when the meter can detect that the strip is loaded with the sample and before a second test potential E2 is applied.
In one aspect, the E1 test potential is small.
For example, the potential can be in the range of about -1 to about -100 mV, preferably in the range of about -5 mV to about -50 mV and, most preferably, in the range of about -10 mV to about -30 mV.
The lower potential agitates the reduced mediator concentration gradient to a lesser extent compared to applying a larger potential difference, but it is still sufficient to obtain a measurement of the oxidizable substances in the sample.
The test potential E1 can be applied for a portion of the time between load detection and when the second test potential E2 is applied or can be applied throughout that period of time.
If test potential E1 is to be used for a portion of the time, then an open circuit could be applied for the remainder of the time.
The combination of any number of open circuit applications and small voltage potential, their order and times applied is not critical in this modality, it can be applied as long as the total period for which the small potential E1 is applied is sufficient to obtain a current measurement indicating the presence and / or the amount of oxidizable substances present in the sample.
In a preferred modality, the small potential E1 is applied for the substantial totality of the period between when a load is detected and when the second test potential E2 is applied.
During the first time interval t1, test meter 100 measures the first resulting current transient, which can be termed ia (t). A current transient represents a plurality of current values measured by a test meter over a particular test potential time interval.
The first current transient can be an integral of current values over the first test potential time interval, or a single average or current value measured during the first test potential time interval multiplied by the time interval of the first test potential time interval.
In some embodiments, the first current transient may include current values measured over several time intervals during the first test potential time interval.
In one embodiment, the first current transient ia (t) can be measured for an instant in the range of about 0.05 seconds to about 1.0 seconds, and preferably in the range of about 0, 1 second to about 0.5 second, and most preferably in the range of about 0.1 second to about 0.2 second.
In other modalities, the first ia (t) transient can be measured by other desired time bands.
As discussed below, a portion or all of the first current transient can be used in the methods described here to determine whether a control solution or blood sample has been applied to test strip 62. The magnitude of the first current transient is affected by the presence of easily oxidizable substances in the sample.
The sage usually contains endogenous and exogenous compounds that are easily oxidized at the second electrode 164. Conversely, the control solution can be formulated so that it does not contain oxidizable compounds.
However, the blood sample composition may vary and the magnitude of the first current transient for high viscosity blood samples will typically be smaller than low viscosity samples (in some cases, even less than control solution samples) ) due to the fact that the sample reaction chamber 61 cannot be fully charged after about 0.2 second.
An incomplete charge will cause the effective area of the first electrode 166 and the second electrode 164 to decrease, which in turn will cause the first current transient to decrease.
In this way, the presence of oxidizable substances in a sample, by itself, is not always a sufficient discriminatory fact due to variations in blood samples.
Once the first time interval t1 has elapsed, test meter 100 can apply a second test potential E2 between the first electrode 166 and the second electrode 164 (for example, about -300 mV as illustrated in Figure 7A) for a second time interval of test potential t2 (for example, about 3 seconds as illustrated in Figure 7A). The second E2 test potential can be a sufficiently negative value of the mediator redox potential so that a limiting oxidation current occurs in the second electrode 164. For example, 5 during use of ferricyanide and / or ferrocyanide as the mediator, the second E2 test potential can be in the range of about -600 mV to about zero mV, preferably in the range of about -600 mV to about -100 mV, and more preferably, be about -300 mV. Likewise, the time interval indicated as the tcap in Figure 6 can also have a duration in the range of instants, but, in an exemplary mode, it lasts for about 20 milliseconds. In an exemplary embodiment, the overlapping alternating test voltage component is applied after about 0.3 seconds to about 0.32 seconds after applying the second test potential E2, and induces two cycles of a sine wave that it has a frequency of about 109 Hz with an amplitude of about +/- 50 mV. During the second test potential time interval t2, test meter 100 can measure a second current transient ib (t). The second time interval of test potential t2 can be long enough to monitor the rate of generation of reduced mediator (e.g., ferrocyanide) in the sample reaction chamber 61 based on the magnitude of a limiting oxidation current. The reduced mediator can be generated by a series of chemical reactions in the reagent layer
72. During the second test potential time interval t2, a limited amount of reduced mediator is oxidized at the second electrode 164 and a non-limiting amount of oxidized mediator is reduced at the first electrode 166 to form a concentration gradient between the first electrode 166 and second electrode 164. As will be described, the second time interval for test potential t2 should be long enough so that a sufficient amount of ferricyanide can be generated in the second electrode 164. A sufficient amount of ferricyanide may be required at the second electrode 164 so that a limiting current can be measured for ferrocyanide oxidation at the first electrode 166 during the third E3 test potential. The second time interval of test potential t2 can be in the range of about 0 seconds to about 60 seconds and, preferably, in the range of about 1 second to about 10 seconds, and most preferably, in the range from about 2 seconds to about 5 seconds.
Figure 7B shows a relatively small peak ipb at the beginning of the second test potential time interval t2 followed by a gradual increase in an absolute value of an oxidation current during the second test potential time interval (for example , in the range of about 1 second to about 4 seconds). The small peak occurs due to an initial depletion of mediator reduced by about 1 second.
The gradual increase in the oxidation current is attributed to the generation of ferrocarbon by the reagent layer 72 followed by its diffusion to the second electrode 164. After the second time interval of potential t2 has elapsed, the test meter 100 can apply a third test potential E3 between the first electrode 166 and the second electrode 164 (for example, about +300 mV as shown in Figure 7A) for a third time interval of test potential t3 (for example, in the about 4 to about 5 seconds as shown in Figure 6). During the third test potential time interval t3, test meter 100 can measure a third current transient, which can be called ic (t). The third E3 test potential can be a sufficiently positive value of the mediator redox potential so that a limiting oxidation current is measured at the first electrode 166. For example, when using ferricyanide and / or ferrocyanide as the mediator, the The magnitude of the third E3 test potential can be in the range of about zero mV to about 600 mV, preferably in the range of about 100 mV to about 600 mV, and more preferably, be about 300 mV.
The second test potential time interval t2 and the third test potential time interval t3 can each be in the range of about 0.1 second to about 4 seconds.
For the modality shown in Figure 7A, the second t2 test potential time interval was about 3 seconds and the third t3 test potential time interval was about 1 second.
As mentioned above, an open circuit potential time period can be allowed to elapse between the second E2 test potential and the third E3 test potential. Alternatively, the third E3 test potential can be applied after applying the second E2 test potential. Note that a portion of the first, second, or third current transient can generally be called a cell current or a current value.
The third time interval of the t3 test potential can be long enough to monitor the diffusion of a reduced mediator (eg, ferrocyanide) near the first electrode 166 based on the magnitude of the oxidation current.
During the third t3 test potential time interval, a limited amount of reduced mediator is oxidized on the first electrode 166 and a non-limiting amount of oxidized mediator is reduced on the second electrode 164. The third potential time interval t3 test range can be in the range of about 0.1 second to about 5 seconds and, preferably, in the range of about 0.3 second to about 3 seconds, and most preferably, in the range of about 0.5 seconds to about 2 seconds.
Figure 7B shows a relatively large peak ipc at the beginning of the third test potential time interval followed by a decrease for a steady-state current.
In one embodiment, the first test potential E1 and the second test potential E2 have a first polarity, and the third test potential E3 has a second polarity, which is opposite to the first polarity.
However, the applicant notes that the polarity of the first, second and third test potentials can be chosen depending on the way in which the analyte concentration is determined and / or depending on the way in which the test samples and the solutions of control are distinguished.
Capacitance measurement In some modalities, capacitance can be measured.
Capacitance measurement can essentially measure a double layered capacitance resulting from the formation of ionic layers in the electrode and liquid interface.
A capacitance magnitude can be used to determine whether a sample is the control solution or a blood sample.
For example, when the control solution is inside the reaction chamber, the magnitude of the measured capacitance may be greater than the magnitude of the measured capacitance when the blood sample is in the reaction chamber.
As will be discussed in more detail below, a measured capacitance can be used in various methods to correct the effects of changes in a physical property of the electrochemical cell in measurements made using the electrochemical cell.
For example, changes in measured capacitance can be related to at least one of an electrochemical cell's age and an electrochemical cell's storage condition.
As a non-limiting example, the methods and mechanisms for carrying out capacitance measurements on test strips can be found in US Patent Nos. 7,195,704 and 7,199,594, each is incorporated herein by reference in its entirety .
In an example method for measuring capacitance, a test voltage that has a constant component and an oscillating component is applied to the test strip.
In such an example, the resulting test current can be mathematically processed, as described in more detail below, to determine a capacitance value.
In general, when a limiting test current occurs at a working electrode that has a well-defined area (that is, an area that does not change during capacitance measurement), the most accurate and precise capacitance measurements on a strip electrochemical testing can be performed.
A well-defined electrode area that does not change over time can occur when there is a tight seal between the electrode and the spacer.
The test current is relatively constant when the current does not change rapidly due to analyte oxidation or electrochemical loss.
Alternatively, any period of time during an increase in the signal, which would be observed due to analyte oxidation, is effectively balanced by a decrease in the signal, which accompanies the electrochemical loss, can also be an appropriate time interval for the capacitance measurement. 5 An area of the first electrode 166 can potentially change over time after dosing with the sample if the sample penetrates between the spacer 60 and the first electrode 166. In a test strip embodiment, the reagent layer 72 can have an area larger than the cutout area 68 which means that a portion of the reagent layer 72 is between the spacer 60 and the first electrode layer 66. Under certain circumstances, the interposition of a portion of the layer reagent 72 between the spacer 60 and the first electrode layer 66 can allow the wet electrode area to increase during a test.
As a result, a leak can occur during a test, which causes the area of the first electrode to increase over time, which in turn can distort a capacitance measurement.
In contrast, an area of the second electrode 164 may be more stable over time compared to the first electrode 166 due to the fact that there is no reagent layer between the second electrode 164 and the spacer 60. Thus, it is likely that the sample penetrate between spacer 60 and second electrode 164. A capacitance measurement using a limiting test current on the second electrode 164 can therefore be more accurate due to the fact that the area does not change during the test.
As discussed above and as shown in Figure 7A, once the liquid is detected on the test strip, the first test potential E1 (for example, about -20 mV, as shown in Figure 7A) can be applied between the electrodes for about 1 second to monitor the liquid loading behavior and to distinguish between the control solution and the blood.
In Equation 1, test currents of about 0.05 to about 1 second are used.
This first E1 test potential can be relatively low so that the distribution of ferrocyanide in the cell is interrupted as little as possible by the electrochemical reactions that occur.
on the first and second electrodes.
A second E2 test potential (for example, about -300 mV, as shown in Figure 7A) that has a greater absolute magnitude can be applied after the first E1 test potential so that the limiting current can be measured on the second electrode 164. The second test potential E2 may include an AC voltage component and a DC voltage component.
The AC voltage component can be applied in a predetermined amount of time after the application of the second test potential E2, and, in addition, it can be a sine wave that has a frequency of about 109 Hertz and an amplitude of about + / -50 millivolts.
In a preferred embodiment, the predetermined amount of time can be in the range of about 0.3 seconds to about 0.4 seconds after applying the second test potential E2. Alternatively, the predetermined amount of time can be a time when a test current transient versus time has a slope of about zero.
In another embodiment, the predetermined amount of time may be a time required for a peak current value (eg, ipb) in relation to the loss of 50%. For the DC voltage component, this can be applied at the beginning of the first test potential.
The DC voltage component may be of sufficient magnitude to cause a limiting test current in the second electrode, for example, about -300 mV in relation to the second electrode.
Consistent with Figure 4B, the reagent layer 72 is not applied as a coating on the second electrode 164, which makes the magnitude of the absolute peak current ipb relatively low compared to the magnitude of the absolute peak current ipc.
The reagent layer 72 can be configured to generate a reduced mediator in the presence of an analyte, and the amount of the reduced mediator near the first electrode can contribute to the relatively high absolute peak current ipc.
In one embodiment, at least the enzyme portion of the reagent layer 72 can be configured to not substantially diffuse from the first electrode to the second electrode when the sample is introduced into the test strip. The test currents after ipb tend to settle on a flat region in approximately 1.3 seconds, and then the current increases again while the reduced mediator generated at the first electrode 166, 5 which can be coated with the reagent 72, diffuses to the second electrode 164, which is not coated with the reagent layer
72. In one embodiment, a capacitance measurement can be performed in a relatively flat region of the test current values, which can be performed in about 1.3 seconds to about 1.4 seconds. In general, if the capacitance is measured before 1 second, then the capacitance measurement can interfere with the first relatively low test potential E1 that can be used to measure the first current transient ia (t). For example, an oscillating voltage component in the order of ± 50 mV superimposed over a constant voltage component of -20 mV can cause significant disturbance of the measured test current. The oscillating voltage component not only interferes with the first test potential E1 (but it can also significantly disturb the test currents measured in about 1.1 seconds, which, in turn, can interfere with the correction for antioxidants. of a large number of tests and experiments, it was finally determined that, surprisingly, the measurement of capacitance in about 1.3 seconds to about 1.4 seconds resulted in accurate and precise measurements that do not interfere with the test of discrimination. control / blood solution or blood analyte algorithm (eg glucose). After the second E2 test potential, the third E3 test potential (for example, about +300 mV, as shown in Figure 7A ) can be applied by having the test current measured at the first electrode 166, which can be coated with reagent layer 72. The presence of a reagent layer at the first electrode can allow liquid to penetrate between the spacer layer and the electrode layer, which can cause the electrode area to increase. As illustrated in Figure 7A, in an exemplary mode
a test voltage of 109 Hz (peak to peak ± 50 mV) can be applied for 2 cycles during the tcap time interval.
The first cycle can be used as a conditioning pulse and the second cycle can be used to determine capacitance.
The capacitance estimate can be obtained by adding the test current over a portion of the alternating current (AC) wave, subtracting the direct current deviation (CD) and normalizing the result using the voltage amplitude of AC test and AC frequency.
This calculation provides a measurement of the strip capacitance, which is dominated by the strip sample chamber when it is loaded with a sample.
In a blood glucose assay mode, capacity can be measured by adding the test current over a quarter of the AC wave on each side of the time when the incoming AC voltage crosses the CD offset , that is, when the AC component of the input voltage is zero (the zero crossing point). A derivation of how this translates to a capacitance measurement is described in more detail below.
Equation 1 can show the magnitude of the test current as a function of time during the tcap time interval:
where the terms i0 + st represent the test current caused by the constant test voltage component.
In general, the current component CD is considered to change linearly over time (due to the glucose reaction in progress that generates ferrocyanide) and is thus represented by a constant i0, which is the current CD at time zero (the zero crossing point), es, the slope of the DC current change over time.
The AC current component is represented by Isin (ωt + ϕ), where I is the amplitude of the current wave, ω is its frequency, and ϕ is its phase shift in relation to the input voltage wave.
The term ω can also be expressed as 2πf, where f is the frequency of the AC wave in Hertz.
The term I can also be expressed as shown in Equation 2:
where V is the amplitude of the applied voltage signal and ¦Z¦ is the magnitude of the complex impedance.
The term ¦Z ... can also be expressed as shown in Equation 22:
where R is the real part of the impedance and C is the capacitance. 5 Equation 1 can be integrated from a quarter wavelength before the zero crossing point to a quarter wavelength after the zero crossing point to produce Equation 4:
which can be simplified in Equation 5:
Substituting Equation 2 in Equation 1, then Equation 4, and then rearranging, results in Equation 6:
The integral term in Equation 6 can be approximated using the sum of currents shown in equation 7:
where the test currents are added to a quarter wavelength before the zero crossing point to a quarter wavelength after the zero crossing point.
Replacing Equation 7 in Equation 6, Equation 8 is produced:
in which the bypass current of CD i0 can be obtained by averaging the test current over a complete sine cycle around the zero crossing point.
In another embodiment, capacitance measurements can be obtained by adding the currents not around the zero voltage crossover point, but instead around the maximum AC component of the current.
Thus, in Equation 7, instead of adding a wavelength of a quarter on one side of the zero voltage crossing point, the test current can be added to a wavelength of a quarter around the maximum current.
This is equivalent to assuming that the circuit element that responds to AC excitation is a pure capacitor, so ϕ is approximately π / 2. In this way, Equation 5 can be reduced in Equation 9:
This is believed to be a reasonable hypothesis in this case since the uncoated electrode is polarized so that the DC component, or actual, of the current flowing is independent of the voltage applied over the range of voltages used in the excitation of AC .
Consequently, the actual part of the impedance that responds to AC excitation is infinite, suggesting a pure capacitive element.
Equation 9 can then be used with Equation 6 to produce a simplified capacitance equation that does not require an integral approach.
The net result is that the capacitance measurements during the sum of the currents that are not around the voltage crossing point, but, instead, around the maximum AC component of the current, were more accurate.
CS / Blood Discrimination Test In some modalities, a control solution (CS) / blood discrimination test can be performed.
If the CS / blood discrimination test determines that the sample is blood, then a series of steps can be performed, which may include: applying a blood glucose algorithm, hematocrit correction, blood temperature correction and blood temperature checks. error; and if the CS / blood discrimination test determines that the sample is CS (that is, it is not blood), then a series of steps can be performed, which may include: applying a CS glucose algorithm, correcting CS temperature, and error checks.
If there are no 5 errors, then the test meter will emit a glucose concentration, but if there are errors, then the test may give an error message.
In one embodiment, the characteristics of a control solution (CS) are used to distinguish blood control solutions.
For example, the presence and / or concentration of the oxide-reduction species in the sample, the reaction kinetics and / or capacitance can be used to distinguish blood control solutions.
The method disclosed herein may include the step of calculating a first reference value that is representative of the redox concentration in the sample and a second reference value that is representative of the sample's reaction rate with the reagent.
In one mode, the first reference value is an inter- ferent oxidation current and the second reference value is a reaction termination index.
In some embodiments, a third reference value can be calculated by multiplying the first reference value by a capacitance index.
The capacitance index can be any value calculated that is a capacitance or is related to, for example, proportional to, a capacitance value.
The capacitance index, for example, can be a measured capacitance, a known or predetermined capacitance, or any combination thereof.
The capacitance index can also be related to any capacitances mentioned above and an empirically derived constant.
In an exemplifying modality, the capacitance index can be a ratio between a known capacitance and a measured capacitance or a ratio between a measured capacitance and a known capacitance.
The known capacitance can be an average capacitance measured when blood samples are loaded on test strips of the same type as the test strip being used for the current test.
The measured capacitance can be measured using the algorithm discussed above, for example.
In one embodiment, a CS and blood discrimination test can include a first reference value and a second reference value.
The first value can be calculated based on the current values within the first time interval t1 and the second reference value can be based on current values during the second time interval t2 and the third time interval t3. In one embodiment, the first reference value can be obtained by making a sum of the current values obtained during the first time current transient when using the test voltage waveform in Figure 7A.
As a non-limiting example, a first isum reference value can be represented by Equation 10A:
where the term isum is the sum of current values and t is an instant.
In some modalities, the first reference value can be multiplied by a capacitance index where the capacitance index can be a ratio between a known capacitance and a measured capacitance.
In such modalities, a third icapsum reference value can be represented by Equation 10B:
where Cav is a known mean capacitance, Cm is a measured capacitance, and t is an instant.
In an example model of Equation 10B, the ratio between Cav and Cm can be called the capacitance index.
In an exemplary embodiment, the known average capacitance Cav for an exemplary test strip according to an embodiment of the present invention is about 582 nanofarads.
The second reference value, sometimes called the residual reaction index, can be obtained using a Y-ratio of current values during the second time interval and the third time interval, as shown in Equation 11:
where abs represents an absolute value function and 3.8 and 4.15 represent the time in seconds of the second and third time intervals, respectively, for this particular example.
A discrimination criterion can be used to determine whether the sample is a control or blood solution based on the first reference value in Equation 10A or the third reference value in Equation 10B, and the second reference in Equation 11. For example, the first reference value of Equation 10A or the third reference value of Equation 10B can be compared to a predetermined threshold and the second reference value of Equation 11 can be compared to a predetermined threshold function.
The predetermined threshold can be, for example, about 12 microamperes.
The predetermined threshold function can be based on a function using the first reference value in Equation 10A or Equation 10B.
More specifically, as illustrated by Equation 12, where the calculated value of isum in Equation 10A or icapsum in Equation 10B is represented by X, the predetermined threshold function Fpdt can be:
where Z can be a constant, for example, about 0.2. In this way, the CS / Blood discrimination test can identify a sample as blood if isum in Equation 10A or icapsum in Equation 10B is greater than or equal to the predetermined threshold, for example, about 12 microamperes, and if the Y ratio of values of current during the second time interval and the third time interval, as shown in Equation 11, is less than the value of the predetermined threshold function Fpdt, otherwise the sample is a control solution.
In one embodiment, the CS / blood discrimination test can also be represented, for example, by Equation 13:
then the sample is blood, or control solution. Non-limiting examples of the modalities discussed above include those described in Patent Application No. US 12 / 895,067 by Chaletier et al., entitled "Systems and Methods of Discriminating Between a Con - 5 Sample trolley and a Test Fluid Using Capacitance "and filed on September 10, 2010, and in Patent Application No. US 12 / 895,168 by Chatelier et al., Entitled" Systems and Methods for Improved Stability of Electrochemistry Sensors "and deposited on September 30, 2010, each here incorporated as a reference in its entirety.
Blood Glucose Algorithm If the sample is identified as a blood sample, a blood glucose algorithm can be performed on the test current values.
Assuming that a test strip has an opposite face or face-facing arrangement as shown in Figures 1A-4B, and that a potential waveform is applied to the test strip as shown in Figure 7A or Figure 8A, a first G1 analyte concentration can be calculated using a glucose algorithm as shown in Equation (Eq.) 14:
In Equation 14, G1 is the glucose concentration, i1 is a first current value, ir is a second current value and i2 is an antioxidant-corrected current value, and the terms p, zgr and a are empirically derived derivation constants.
For example, p can be about 0.5246; a can be about 0.03422; and zgr can be about 2.25. In an embodiment of the invention, p can be in the range of about 0.2 to about 4, and preferably, about 0.1 to about 1. The calibration factor a is specific to particular dimensions of the electrochemical cell.
A calibration factor zgr is used to represent the typical background signal that arises from the reagent layer.
A presence of an oxidizable species in the reagent layer of the cell before addition and an sample can contribute to a background signal.
For example, if the reagent layer was to contain a small amount of ferrocyanide (for example, reduced mediator) before the sample was added to the test strip, then there would be an increase in the test current as it would not be assigned to the analyte concentration.
Due to the fact that this would cause a constant 5 bias in the overall measured test current for the test strips, this bias can be corrected with the use of the calibration factor zgr.
Similar to the terms p and a, zgr can also be calculated during the calibration process.
Exemplary methods for calibrating strip batches are described in U.S. Patent No. 6,780,645 which is hereby incorporated by reference in its entirety.
A derivation of Equation 13 can be found in a pending Published Patent Application No. US 2007/0074977 (US Serial Application No. 11 / 240,797), filed September 30, 2005 and titled "Method and Apparatus for Rapid Electrochemical Analy - sis ", the whole of which is incorporated by reference.
All test current values (for example, i1, ir and i2) in Equation 13 use the absolute value of the current.
In one embodiment, the current value ir can be calculated from the third current transient and current value i1 can be calculated from the second current transient.
All current values (for example, i1, ir and i2 established in Equation 14 and in subsequent equations can use the absolute current value.
The current values ir, i1, may, in some embodiments, be an integral of current values over a time span of a current transient, a sum of current values over a time span of a transient current value or an average or single current value of a current transient multiplied by a time interval of the current transient.
For the sum of current values, a range of consecutive current measurements can be added together of just two current values or to all current values.
The current value i2 can be calculated as discussed below.
For example, where an analyte test time interval is 5 seconds long, i1 can be the sum of currents from 3.9 to 4 seconds.
seconds of a 5 second time period and ir can be the sum of currents from 4.25 to 5 seconds of the 5 second analyte test time interval, as shown in Equation 15 A and 15B, below.
A magnitude of the current for the first current transient can be described as a function of time by Equation 16.
The term iss is the steady state current after the application of the second test potential E2, D is the diffusion coefficient of the mediator, L is the thickness of the spacer. It should be noted that, in Equation 16, t refers to the time elapsed after the second E2 test potential has been applied. A current magnitude for the third current transient can be described as a function of time by Equation 17.
There is a factor of two differences for the exponential time in Equation 17 compared to the exponential term in Equation 16 due to the fact that the third current transient is generated from the third E3 test potential, which has polarity opposite to the second E2 test potential. , and was applied immediately after the second E2 test potential. It should be noted that, in Equation 17, t refers to the time that elapsed after the third E3 test potential was applied. A peak current for the second test potential time interval t2 can be denoted as ipb and a peak current for the third test potential time interval t3 can be denoted as ipc. If the second peak current ipb and the third peak current ipc were measured in the same short time after the application of the second test potential E2 and the third test potential E3 respectively, for example, 0.1 second, Equation 16 can be subtracted Equation 17 to yield Equation 18.
Due to the fact that it has been determined that ipb is mainly controlled by interferers, ipc can be used with ipb together to determine a correction factor. For example, as shown below, ipc can be used with ipb in a mathematical function to determine a corrected current that is proportional to glucose and less sensitive to interference. Equation 19 was derived to calculate a current i2 that is proportional to the concentration of analyte and has a relative fraction of current removed that is attributed to interferers.
The term ipb represents a peak current value for the second t2 test potential time interval and the term ipc represents a peak current value for the third t3 test potential time interval. The term iss is an estimate of the steady state current, which is the current expected to occur over long periods after the application of the third test potential E3 in the absence of chemical reactions in progress. The term iss was added to the numerator and to the denominator of Equation 19 to allow the numerator to approach zero when no glucose is present. Some examples of methods for calculating iss can be found in U.S. Patent Nos. 5,942,102 and 6,413,410, each of which is incorporated herein by reference in its entirety. The use of peak current values to represent interferents in a physiological sample is described in Published Patent Application No. US 2007/0227912 (Patent Application No. Serial No. 11 / 278,341), filed March 31 2006 and entitled "Methods and Apparatus for Analyzing a Sample in the Presence of Interferents," all of it is hereby incorporated by reference
reference. In an exemplary modality, the current value corrected by antioxidant i2 can be calculated according to Equation 20.
In Equation 20, i (4.1) comprises an absolute value of the current during a third electrical potential E3; i (1.1) comprises an absolute value of the current during a second electrical potential E2; and iss comprises a steady-state current. In some modalities, iss can be calculated according to Equation 21.
In Equation 21, i (5) comprises an absolute value of the current during a third electrical potential; π comprises a constant; D comprises a diffusion coefficient of an oxide-reduction species, and L comprises a distance between the two electrodes. In some embodiments, a second analyte concentration value can be calculated based on the first analyte concentration value G1. For example, Equation 22 can be used to calculate a second G2 analyte concentration value that de-emphasizes kinetic correction at low analyte concentrations.
In Equation 22, p can be about 0.5246; a can be about 0.03422; i2 can be an antioxidant corrected current value; AFO can be about 2.88; zgr can be about 2.25; and k can be about 0.0000124. By subtracting a deviation from the AFO asymmetry factor from the asymmetry factor ir / i1 and raising the new smaller asymmetry factor term in relation to a power term dependent on analyte concentration, the kinetic correction effect in low analyte concentrations can be de-emphasized.
As a result, a higher level of accuracy over a wide range of analyte concentrations can be achieved.
The example illustrated in Figures 7A and 7B shows the polarity of the first and second voltages applied as negative with a third voltage applied as positive when the electrode that is not coated with reagent acts as the reference electrode for the voltage measurement.
However, the applied voltages can have polarity opposite to the sequence shown in Figure 7A if the electrode that is coated with reagent acts as the reference electrode for the voltage measurement.
For example, in the preferred mode of Figures 8A and 8B, the polarity of the first and second applied voltages is positive with the polarity of the third applied voltage as negative.
In both cases, the glucose calculation is the same due to the fact that the electrode that is not coated with reagent acts as the anode during the first and second applied voltages, and the electrode that is coated with reagent acts as the anode during the third applied voltage.
In addition, if the test meter determines that the sample is a control solution (as opposed to blood), the test meter can store the glucose concentration resulting from the control sample so that a user can review the control data. test sample concentration separately from control solution data.
For example, glucose concentrations for control solutions can be stored in a separate database, can be labeled and / or discarded (that is, not stored or stored for a short period of time). Another advantage of having the ability to recognize a control solution is that a test meter can be programmed to automatically compare the results (for example, glucose concentration) of the control solution test to the expected glucose concentration of the control solution.
For example, the test meter can be pre-programmed with the expected glucose level (s) for the control solution (s).
Alternatively
tively, a user could enter the expected glucose concentration for the control solution.
When the test meter recognizes a control solution, the test meter can compare the measured control solution glycoside concentration to the expected glucose concentration to determine if the meter is functioning properly.
If the measured glucose concentration is outside the expected range, the test meter may issue a warning message to alert the user.
Temperature Correction In some modalities of systems and methods, a blood temperature correction can be applied to the test current values in order to provide an analyte concentration with improved accuracy due to a reduced temperature effect .
A method for calculating a temperature-corrected analyte concentration may include measuring a temperature value and calculating a temperature value correction CT.
The temperature value correction CT can be based on a temperature value and an analyte concentration, for example, a glucose concentration.
Consequently, the temperature value correction CT can then be used to correct the analyte concentration for the temperature.
Initially, an analyte concentration uncorrected for temperature can be obtained, such as a G2 analyte concentration from Equation 22 above.
A temperature value can also be measured.
The temperature can be measured using a thermistor or another temperature reading device that is incorporated into a test meter, or by countless mechanisms or means.
Subsequently, a determination can be made to determine whether the temperature value T is greater than a first temperature threshold T1. For example, the temperature threshold T1 can be about 15 ° C.
If the temperature value T is greater than 1 ° C, then a first temperature function can be applied to determine the temperature value correction CT.
If the temperature value T is not greater than 1 ° C, then a second temperature function can be applied to determine the temperature value correction CT.
The first temperature function for calculating the CT temperature value correction can be in the form of Equation 23:
where CT is the correction value, K9 is a ninth constant (for example, -0.866), T is a temperature value, TRT is an ambient temperature value (for example, 22 ° C), K 10 is one tenth constant (for example, 0.000687), and G2 is the analyte concentration.
When T is approximately equal to TRT, CT is approximately zero.
In some examples, the first temperature function can be configured to have essentially no correction at room temperature so that the variation can be reduced under routine room conditions.
The second temperature function for calculating the second CT correction value can be in the form of Equation 24:
where CT is the correction value, K11 is an eleventh constant (for example, -0.866), T is a temperature value, TRT is an ambient temperature value, K12 is a constant twelfth (for example, 0 , 000687), G2 is an analyte concentration, K13 is a thirteenth constant (for example, -0,741), T, is a first temperature threshold (for example, about 15 ° C), and K 14 is a tenth fourth constant (for example, 0.00322). After CT is calculated using Equation 23, a pair of truncation functions can be performed to ensure that CT is within a predetermined range, thus mitigating the risk of an outlier.
In one embodiment, CT can be limited to a range of -10 to +10. For example, a determination can be made to determine whether C is greater than 10. If C is greater than 10, and the temperature is above a threshold value, for example, 15 ° C, then CT is set to 10. If CT is not greater than 10, then a determination is made to determine whether CT is less than -10. CT can be set to -10 if CT is less than -10. If CT is already between -10 and +10, then, in general, there is no need for truncation.
However, if the temperature is less than a threshold value,
for example, 15 ° C, so the maximum C T value can be set to 10 + 0.92 (15-T). Once CT is determined, a temperature-corrected analyte concentration can be calculated.
For example, a determination 5 can be performed to determine whether the analyte concentration uncorrected for temperature (eg, G2) is less than 100 mg / dl.
If G2 is less than 100 mg / dl, then an equation 25 can be used to calculate the G3 temperature corrected analyte concentration by adding the CT correction value to the G2 glucose concentration:
If G2 is not less than 100 mg / dl, then an equation 26 can be used to calculate the G2 temperature-corrected analyte concentration by dividing CT by one hundred, adding one; and then multiplying by the G2 analyte concentration (this approach effectively uses CT as a percentage correction term):
Once an analyte concentration has been determined that has been corrected for the effects of temperature, an additional correction can be made based on the sample loading time.
Loading Time Correction In some modalities, the analyte concentration can be corrected on the basis of the sample loading time.
An example of such a method is revealed in a copending patent application entitled "Systems, Devices and Methods for Improving Accuracy of Biosensors Using Fill Time" by Ronald C.
Chatelier and Alastair M.
Hodges, (Order No. 12 / 649,594) filed December 30, 2009, and "Systems, Devices and Methods for Improving Accuracy of Biosensors Using Fill Time", by Ronald C.
Chatelier and Alastair M.
Hodges, (Order No. Serial 12 / 971,777) filed on December 17, 2010, both are incorporated herein by reference in their entirety.
In an alternative modality for detecting an analyte concentration in a sample, errors based on a determined initial loading speed instead of a determined loading time can be corrected. An example of such a method is revealed in a copending patent application entitled "Systems, Devices and Methods for Measuring Total Blood Haematocrit Based on Initial Fill Velocity", by Ronald C. Chatelier, Dennis Rylatt, Linda Raineri and Alastair M. Hodges, ( Order No. 5 of Series 12 / 649,509) deposited on December 30, 2009, which is incorporated in its entirety by reference title. In exemplary modalities of the corrections for the loading time discussed above, the temperature-corrected analyte concentration G3 can be corrected in view of the loading time to yield a time-corrected analyte concentration value for the G4 loading according to Equations 27A and 27B, below. For example, when G3 <100 mg / dl, no correction is needed and G4 may be the uncorrected value for G3. However, when G3> 100 mg / dl, G3 can be corrected using Equation 27B in conjunction with Equations 28A, 28B and 28C.
The CFT correction factor in Equation 27B can be calculated in view of the load time (FT) based on a series of FT threshold values. For example, the following equations can be used to calculate CFT using two threshold values for FT, Th1 and Th2.
In an exemplary embodiment, the threshold value Th1 can be about 0.2 seconds, the threshold value Th2 can be about 0.4 seconds and the load time factor FTf can be around 41. For example, when blood charges the sensor in less than about 0.2 seconds, so its charging behavior can be described as close to ideal.
Loading times less than about 0.2 seconds usually occur when the hematocrit is so low that the sample viscosity has a minimal effect on the loading behavior of the sample.
As a consequence of the low hematocrit, it is believed that most of the glucose is broken down to form the plasma phase in which it can be quickly oxidized.
Under these conditions, there is little need to correct the glucose result for the loading time effect, and then the correction factor can be set to zero.
Alternatively, when the hematocrit in the sample is high, the viscosity of the sample can affect the sample loading time.
As a result, the sample may take more than about 0.4 seconds to load the sensor.
As a consequence of high hematocrit, it is believed that most of the glucose is broken down to form red blood cells and then a lower fraction of the glucose is oxidized.
Under these conditions, the glucose result can be corrected in view of the loading time.
However, it may be important not to over-correct the glucose value, and then, in an exemplary embodiment, the correction factor may be restricted to a maximum of about 10 mg / dl of plasma glucose or about 10% of the signal.
An empirically derived linear equation can be used to gradually increase the correction term in the range of about 0 to about 10 while the charge time increases in the range of about 0.2 to about 0.4 seconds.
Age / Storage Correction In some modalities of the systems and methods of the present invention, an additional correction factor can be applied to the load time corrected analyte concentration value G4. This correction factor can be used to provide improved accuracy by correcting the effect of age and / or storage conditions on sensor performance.
For example, a parameter correlated to a physical property of the sensor can be measured and this parameter can be used to calculate the corrected analyte concentration.
In some modalities, the parameter correlated to a physical property of the sensor can be a capacitance.
measure of the sensor.
The measured capacitance of the sensor, for example, an electrochemical cell of the type described in more detail above, may be related to the age and / or storage conditions of the sensor.
As a non-limiting example, the capacitance of an electrochemical cell can be affected by the slow flow of the adhesive used in the manufacture of the spacer layer electrochemical cell in the sample reaction chamber.
As the sensor ages, as during storage, particularly at high temperatures, the adhesive can flow into the reaction chamber and cover the sensor reference electrodes and / or counter electrodes.
For example, the adhesive can cause a reduction in the area of the electrodes, which can affect the accuracy of measurements made by the sensor.
The reduction in the electrode area can also be correlated with a reduction in the capacitance of the sensor.
Therefore, the measured capacitance of the sensor can be used to calculate a correction factor that can be used to improve the accuracy of readings taken using the sensor.
In an exemplary embodiment, a method for calculating a corrected analyte concentration may include measuring a physical property of the electrochemical cell, for example, a capacitance, and calculating a correction factor Cc. The correction factor Cc can be based on the measured physical property.
Consequently, the correction factor Cc can be used to calculate a corrected analyte concentration.
Initially, an analyte concentration can be obtained, such as the G4 loading time corrected analyte concentration value above.
A measured capacitance of the sensor can also be obtained, for example, using the capacitance measurement methods discussed above.
Subsequently, a determination can be made to determine whether the measured capacitance value C is less than a threshold value of capacitance C1. In some embodiments, the threshold value for capacitance C1 can be an average or ideal capacitance of sensors of the same type.
If the capacitance value C is less than the threshold value of capacitance C1 and if the con-
Uncorrected (or previously corrected) analyte concentration G4 is greater than a Gth analyte concentration threshold, so a capacitance correction function can be used to determine the correction factor Cc.
If the capacitance value C is not less than the threshold value of capacitance C1 and / or if the uncorrected (or previously corrected) analyte concentration G4 is not greater than the analyte concentration threshold Gésimo, then the correction factor Cc can be set to zero.
For example, in a modality, the threshold value for capacitance C1 can be about 577 nanoFarad and the analyte concentration threshold Gésimo, for example, a glucose concentration, can be about 100 mg / dl.
Consequently, if the capacitance value C and / or the concentration of analyte G4 are within the predetermined range (s), the correction factor Cc can be determined using a capacitance correction function. , otherwise, the correction factor Cc can be set to zero.
The capacitance correction function for calculating a capacitance correction factor Cc when the measured capacitance value C is less than the threshold value of capacitance C1 and the uncorrected (or previously corrected) analyte concentration G4 is greater than one analyte concentration threshold Gésimo can be in the form of Equation 29:
where Cc is the correction factor, Kc is an empirically derived constant (for example, 0.051), C1 is the threshold capacitance value (for example, 577 nanoFarad), and C is the measured capacitance value.
After Cc is calculated, for example, using Equation 29, a pair of truncation functions can be performed to ensure that Cc is restricted to a predetermined range, thus mitigating the risk of an outlier by limiting the correction maximum applied to the data.
In one embodiment, if Cc is greater than a cutoff value, Cc can be set to the cutoff value.
For example, a determination can be made to determine whether Cc is greater than a cutoff value, for example, 5. If Cc is greater than the cutoff value, for example, 5, then Cc is set to the cutoff value, for example, 5. If Cc is not greater than the cutoff value, then there is, in general, no need for truncation.
Once Cc is determined, a capacitance-corrected analyte concentration can be calculated.
For example, a determination can be made to determine if the G4 non-corrected (or previously corrected) analyte concentration is less than a Gésimo analyte concentration threshold, for example, 10 mg / dl if the analyte is glucose.
If G4 is less than the Gth analyte concentration threshold, then no further correction is applied.
If G4 is greater than the analyte concentration threshold Gésimo, then an equation 30 can be used to calculate the capacitance corrected glucose concentration (or final concentration value) G5 by dividing Cc by one hundred, adding one, and , then, multiplying by the analyte concentration [G]:
Once an analyte concentration has been determined that has been corrected for the purposes of age and / or storage, the analyte concentration can be output, for example, to a display.
As discussed above, the systems and methods of the present invention can achieve an accuracy standard of at least ± 10% for glucose concentrations above a glycoside concentration threshold, so that at least 95% of a series of glucose concentration assessments produce a concentration of glucose value that is accurate within a 10% margin of a reference glucose measurement.
In another example, the method can achieve an accuracy standard of at least ± 10 mg / dl for glucose concentrations below the glucose concentration threshold, so that at least 95% of a series of glucose concentration produces a concentration of glucose value that is accurate within a margin of about 10 mg / dl of a reference glucose measurement.
For example, the glucose concentration threshold can be about 75 mg / dl.
The applicant notes that the algorithms and methods of the present invention can achieve these precision standards over a series of more than about 5,000 analyte concentration assessments and also for more than about 18,000 concentration assessments. analyte.
For example, the systems and methods of the present invention can meet or exceed the standards and recommendations of the US Food and Drug Administration Agency for the accuracy of portable invasive blood glucose monitoring systems.
EXAMPLE 1 The reduction in donor to donor variation in glucose concentration measurements using the current sum time windows discussed above is demonstrated by this example.
In the following example, the system included a sensor with two opposite electrodes, with reagents designed to react with the dry sample on one electrode.
A plurality of samples from different donors has been provided for analysis to test the performance of the systems, devices and methods disclosed here.
The samples were 10,240 blood samples from 31 donors that cover a hematocrit range of 37% to 45%. Current transients were measured and analyzed using a first algorithm that depend on the time windows from about 1.4 seconds to about 4.0 seconds to go and from about 4.4 seconds to about 5 seconds to go.
The measured current transients were also measured using a second algorithm discussed above, specifically the current values ir and il calculated according to Equation 15A and 15B above.
The standard deviation of the test results using the first algorithm was about 2.83. The standard deviation of the test results with the use of the second algorithm shown and described here was about 1.72. This result shows an unexpected improvement in accuracy when the current values ir and il are calculated according to Equation 15A and 15B.
EXAMPLE 2 The reduction in gender to gender variation in glucose concentration measurements using the current sum time windows discussed above is demonstrated by this example.
In the following example, the system included a sensor with two opposite electrodes, with reagents designed to react with the dry sample on one electrode.
A plurality of samples from 30 different donors, 15 males and 15 females, were provided for analysis to test the performance of the systems, devices and methods disclosed here.
Current transients were measured and analyzed using a first algorithm, which included the 5 time windows from about 1.4 seconds to about 4.0 seconds for ii and about 4.4 seconds to about 5 seconds to go.
The measured current transients were also measured using a second algorithm discussed above, specifically the current values ir and ij calculated according to Equation 15A and 15B above.
As shown in Figure 9, blood samples from females tend to have more positive bias than a reference glucose measurement performed by a YSI 2700 clinical instrument (mean bias = 1.6 ± 2.1 SD) and blood samples from males tend to have more negative bias than a reference glucose measurement performed by the YSI 2700 clinical instrument (mean bias = -2.5 ± 1.9 SD). If you stick to any particular theory, it is believed that one reason for gender-to-gender differences is that glucose oxidation kinetics are different in males and in females (perhaps due to variations in the efflux rate glucose in blood cells, or differences in plasma viscosity). The applicant then tested several time windows for the current transients used to determine the glucose concentration in order to determine the time windows in which the observed differences were less apparent.
The time windows in the current transients that yielded the most satisfactory results (ie, lower reference glycoside measurement bias) were the window from about 3.9 seconds to about 4.0 seconds for ii ( see Equation 15B above) and the window from about 4.25 seconds to about 5 seconds to go (see Equation 15A above). As shown in Figure 9, these new time windows reduced the bias of reference glucose measurements performed by the clinical instrument YSI 2700 for male and female donors compared to previous time windows, that is, of about from 1.4 seconds to about 400 seconds for ii and from 4.4 seconds to about 5 seconds to go.
In particular, the bias of reference glucose measurements performed by the YSI 2700 clinical instrument was reduced to an average bias of 0.7 ± 1.6 SD for female donor samples and an average bias of -0.4 ± 1.7 SD for male donor samples. 5 Thus, for both genders, the mean bias was closer to zero and the SD bias was shorter when the time windows in Equations 15A and 15B were used.
EXAMPLE 3 The reduction in urate concentration interference in glucose concentration measurements using the current summation time windows discussed above is demonstrated by this example.
In the following example, the system included a sensor with two opposite electrodes, with reagents designed to react with a dry sample on one electrode.
A plurality of samples have been provided for analysis to test the performance of the systems, devices and methods disclosed herein.
Current transients were measured and analyzed using the first algorithm, which included time windows of about 1.4 seconds to about 4.0 seconds for ii and about 4.4 seconds to about 5 seconds to go.
The current transients measured were also measured using a second algorithm shown and described here, specifically the current values ir and ii calculated according to Equation 15A and 15B.
The bias of reference glucose measurements performed by the YSI 2700 clinical instrument was determined for samples with a target plasma glucose level of 65, 240 or 440 mg / dl.
These data were plotted against the concentration of urate that was enriched in the blood of normal hematocrit.
The slope of each line was calculated.
A low slope shows low urate interference.
As shown in Table 1 below, the bias for the first algorithm was much greater than the bias for the second algorithm discussed above.
More specifically, the current values ir and il calculated according to Equation 15A and 15B showed, surprisingly, 5 to 13 times less sensitivity to blood urate than the first algorithm.
Table 1 [glucose] delta bias per mg / dl Interferent (mg / dl) 1st Algorithm 2nd Algorithm 65 -0.27 0.02 240 -0.50 -0.11 440 -0.43 -0.08 EXAMPLE 4 A The effectiveness of the load time correction algorithms disclosed here for blood that has a high hematocrit content is demonstrated by this example.
In the following example, the system included a sensor with two opposite electrodes, with reagents designed to react with the sample dries on one electrode.
A plurality of samples have been provided for analysis to test the performance of the systems, devices and methods disclosed herein.
The samples were blood samples that contained a hematocrit range of about 15% to about 70%. The algorithms revealed here can compensate for the slow blood load and can accurately report glucose in hematocrits greater than 70%. This has consequences for testing neonates who may have very high hematocrit levels in the first 16 hours after birth.
The glucose bias of reference glucose measurements performed by the YSI 2700 clinical instrument was plotted against hematocrit.
A slope of the most satisfactory line for these data is an indication of hematocrit dependence on the glucose response.
A small slope is more ideal.
When the new time windows, specifically the current values ir and il calculated according to Equation 15A and 15B above, are used to analyze the data obtained with 15 to 70% hematocrit blood, then the slope plot bias versus hematocrit was -0.0278. When the load time correction discussed above was included in the analysis, then the slope decreases to -0.0098. The applicant surprisingly revealed that the loading time correction discussed above reduces the hematocrit dependence on the glucose response by a factor of 2.8. EXAMPLE 5 The improved shelf life of test strips using a capacitance correction algorithm according to the present invention is demonstrated by this example.
The test strips are typically manufactured with a hot-melt adhesive between the two electrodes.
If the sensors are stored at elevated temperatures for an extended period of time, the adhesive can flow slowly and can partially cover the electrodes.
This 5 will reduce the current measured when the voltage is applied.
However, as the electrode area decreases, the measured capacitance value will also decrease.
The change in capacitance can be used to correct the glucose response, as described in the equations above.
A plot of bias versus storage time can be used to estimate the shelf life of the product (noting the time in which the defined line crosses one of the error budget limits). The capacitance correction described above affects only populations with high glucose content (> 100 mg / dl). In practice, a lower slope tends to be related to a longer shelf life.
When capacitance correction is not used, the slope of the bias plot versus storage time is - 0.0559. However, when the data are corrected for changes in capacity, the slope of the bias plot versus storage time decreases to -0.0379. Then, the product will have a shelf life approximately 50% longer when the capacitance correction algorithm discussed above is used to correct for changes in capacitance as the sensors age.
EXAMPLE 6 A greater general precision that results from the correction algorithms discussed above is demonstrated by this example.
In the following example, the system included a sensor with two opposite electrodes, with reagents designed to react with the dry sample on one electrode.
A plurality of samples from different donors was provided for analysis to test the performance of the systems, devices and methods disclosed here.
The data set included 18,970 glucose assays, consisting of: - 7,460 assays for a stability study (6 strip lots stored at 30 ° C / 65% Relative Humidity for 1 to 1 8 months, tested with blood from normal hematocrit enriched in 50, 250 and 500 mg / dl of plasma glucose), - 5,179 temperature study tests conducted at 5 to 45 ° C (tested with normal hematocrit blood), and 5 - 6,331 hematocrit study tests (15 to 70% hematocrit). The data from these trials were analyzed using the algorithms discussed above.
Defining the complete algorithm for this "challenge overdefinition" yielded the following definition parameters, which are discussed in relation to the equations revealed above: Table 2 Parameter K value (G-dep power term) 1.24E -05 P 0.5246 H 0.03422 Zgr 2.25 AF deviation 2.88 T (> 15C) -0.866 TG (> 15C) 0.000687 T (> 15C) -0.741 TG (> 15C) 0.00322 FT fact 41 Deviation of cap 577 Inclination of cap 0.051 The gradual improvement in sensor performance with the addition of each aspect of the algorithm is shown in Table 3, below.
The largest set of data described above was defined, first, with the new time windows only (G1), then with the charge time used to correct G1, then with the capacitance used to correct the previous result, then with the AF deviation ("AFO") used to correct the previous result, and, finally, with the glucose-dependent power term added (to render the complete algorithm). This was done to show the incremental improvement provided by each step of the algorithm.
The main changes are in the results obtained with G> 75 mg / dl.
The improvement in performance observed with each step of the algorithm.
The RMS bias is the medial root bias of the squares between the calculated plasma glucose equivalent and the reference value
measured value.
Bias is expressed in relation to a reference glucose concentration as mg / dl for G <75 mg / dl and as% for G> 75 mg / dl.
P10 refers to the percentage of glucose results that are within 10 mg / dl or 10% of the reference value. 5 Table 3 RMS Bias Component P10 (G <75 mg / dl) P10 (G <75 mg / dl algorithm) New windows of 4.51 99.33 95.30 Time correction- 4.45 99.36 95.77 g of load Cover correction - 4.36 99.45 96.34 citance Factor deviation of 4.27 99.49 96.70 asymmetry Power term 4.25 99.49 96.89 G-dependent O "asymmetry factor deviation" and the "glucose dependent power term" were designed to overcome the tendency for biases to be slightly positive at low glucose and slightly negative at high glucose.
This non-ideal behavior is regularly observed as a negative slope when the bias is plotted against the reference plasma glucose.
The inclusion of "asymmetry factor deviation" and "glucose dependent power term" in the algorithm reduced this negative slope by 26%. This change was sufficient to put 1.55% more points in 10% of the reference plasma glucose value when the glucose level was greater than 80 mg / dl.
The breakdown in results by the data set is shown in Table 4. In each case, P10> 95%, which meets the American Diabetes Association's preferred performance criteria.
Table 4 RMS Bias Set P10 (G <75 P10 (G <75 Count data mg / dl) mg / dl) Hematocrit 3.88 99.25 97.92 6331 Stability 4.25 99.64 96.98 7460 Temperature 4.67 99.51 95.51 5179 The results are also presented graphically in Figures 10 to 14, to allow an evaluation of outliers that are not situated
am within 10 mg / dl or 10% of the reference plasma glucose value.
Figures 10 to 12 show the complete data set plotted against glucose, hematocrit and reference temperature.
Figures 13 to 14 show the stability data divided as G <75 mg / dl and G> 75 mg / dl. The present invention also relates to a method of obtaining an increased accuracy of a test strip which comprises: providing a batch of test strips, each test strip having two separate electrodes with a reagent disposed between the same; introduce a reference sample that contains a reference concentration of one analyte for each batch of test strips; react the analyte to cause a physical transformation of the analyte between the two electrodes; measure the current outputs at discrete intervals to derive a sample filling time at the sensor and a capacitance of the sensor with the sample; determining a first analyte concentration value from the current outputs; calculate a second analyte concentration value from the current outputs and the first analyte concentration; correcting the second analyte concentration value for temperature purposes to provide a third analyte concentration value; correcting the third analyte concentration value as a function of the sensor filling time to provide a fourth analyte concentration value; and correct the fourth analyte concentration value as a function of capacitance to provide a final analyte concentration value for each of the test strip benchtops so that at least 95% of the concentration values of end of the test strip batch are within 10% of the reference analyte concentration.
The present invention also relates to an analyte measurement system comprising: a plurality of test strips, each test strip having at least two separate electrodes in a test chamber and a reagent disposed between them to receive a sample containing an analyte; and an analyte measurement device that includes: a strip port that has connectors configured to be compatible with respective electrodes on each test strip; and a microprocessor
coupled to the strip port and configured to measure current, test strip capacitance and sample fill time with the electrodes of each test strip when a reference sample is deposited in the test chamber of each of the plurality of test strips and a final analyte concentration determined based on the current, sample fill time and test strip capacitance so that a percentage of the final analyte concentration values from of test strips are within 10% of a reference analyte value above a borderline analyte value.
In said system, the microprocessor can be configured so that when an analyte test strip of the plurality of test strips is coupled to the strip port with a sample deposited on it, an analyte in the sample reacts between the two electrodes to supply a first estimate of analyte concentration G1 based on the output current values measured over discrete intervals, the second estimate of analyte concentration G2 based on the output current values measured over discrete intervals, at the value of temperature-corrected analyte concentration G3 from the second analyte concentration value G2, from the analyte concentration value corrected by sample filling time G4 from the third analyte concentration and from the final concentration value corrected by G5 test strip capacitance from the analyte concentration value corrected for sample filling time G4. In addition, discrete intervals can comprise a first interval of about 3.9 seconds to about 4 seconds and a second interval of about 4.25 seconds to about 5 seconds, the first and second intervals being measured from the moment a sample is deposited in the test chamber, where the output current values measured over the first and second intervals comprise a first sum of current ir and a second sum of current il, where:
where i (t) comprises the absolute value of the current measured at time t.
It is noted that the first analyte concentration value G1 can comprise a derivation of the current values with an equation 5 of the form:
wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; and zgr comprises about 2.25. In addition, the second concentration value of analyte G2 may comprise a derivation with an equation of the form:
wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; AFO comprises about 2.88; zgr comprises about 2.25; and k comprises about 0.0000124. The value i2 can also comprise an equation of the form:  i (4.1) - 2i (1.1) + iss  i2 = ir    i (4.1) + iss  where i (4.1 ) comprises an absolute value of the current during a third electrical potential; i (1,1) comprises an absolute value of the current during a second electrical potential; and iss comprises a steady state current.
The iss value can comprise an equation of the form:
where i (5) comprises an absolute value of the current during a third electrical potential; π comprises a constant; D comprises a diffusion coefficient of an oxide-reduction species and L comprises 5 a distance between the two electrodes.
It is noteworthy that the analyte concentration value corrected by temperature G3 can be corrected by a fill time correction factor based on a fill time, with the fill time correction factor comprising about zero when the fill time is less than a first fill time threshold and when the fill time is longer than the first fill time threshold and less than a second fill time threshold, the time correction factor Fill time can be calculated based on the fill time and when the fill time is greater than the second fill time threshold, the fill time correction factor comprises a constant value.
The temperature-corrected analyte concentration value G3 may comprise a first temperature correction for the second analyte concentration value G2 whenever an ambient temperature is greater than the first temperature threshold and a second temperature correction whenever the ambient temperature is lower than for the first temperature threshold.
In addition, the final concentration value corrected by G5 test strip capacitance can be set equal to the fourth analyte concentration value when the analyte concentration value corrected by sample filling time G4 is less than a first concentration threshold.
It is also noted that the final concentration value corrected by test strip capacitance G5 may comprise a product of a capacitance correction factor and the analyte concentration value corrected by sample filling time G4 when the concentration value of analyte corrected for sample filling time G4 is greater than 5 a first concentration threshold, and the capacity correction factor for the final analyte concentration value is based on a measured capacity when the capacitance is lower that a first capacitance threshold and the capacitance correction factor is set to a maximum value when the calculated capacitance correction factor is greater than an established value.
The present invention also relates to a method for determining an analyte concentration in a sample which comprises: introducing a sample that includes an analyte to an electrochemical sensor, the electrochemical sensor comprising two electrodes in a configuration - separate section; react the analyte to cause a physical transformation of the analyte between the two electrodes; determine an analyte concentration; where the method achieves an accuracy standard of at least ± 10% for analyte concentrations above an analyte concentration threshold, so that at least 95% of a series of analyte concentration assessments yield a value of analyte concentration that is needed within a 10% margin of a reference analyte measurement.
The method can achieve an accuracy standard of at least ± 10 mg / dl for analyte concentrations below the analyte concentration threshold, so that at least 95% of a series of analyte concentration assessments yield a concentration value of analyte that is needed within a margin of about 10 mg / dl of a reference analyte measurement.
In addition, the analyte concentration threshold can be approximately 75 mg / dl.
In addition, the standard of precision can be achieved over a series of more than about 5,000 analyte concentration assessments.
Alternatively, the standard of precision can be achieved over a series of more than about 18,000 analyte concentration assessments.
The method can further comprise the step of reducing the variation in determinations of analyte concentration from donor to donor and gender to gender and the step of reducing interference by urate concentration in determining the analyte concentration.
In addition, the step of determining an analyte concentration can include a correction step for one or more of a sample filling time, a physical property of the electrochemical cell, a sample temperature, a sensor temperature electrochemical and glucose reaction kinetics.
Note that the correction step for glucose reaction kinetics can include the steps of: calculating a first analyte concentration, and calculating a second analyte concentration that depends on the first analyte concentration, so that the magnitude of the correction for glucose reaction kinetics is proportional to the magnitude of the first analyte concentration.
In the aforementioned method, the physical property of the electrochemical sensor can be related to at least one of an age of the electrochemical sensor and a storage condition of the electrochemical sensor.
Furthermore, the reaction of the analyte can generate an electroactive species that is measured as a current by the two electrodes.
It is noteworthy that the two electrodes can comprise an orientation facing the opposite side.
In addition, the two electrodes can comprise a forward orientation.
In said method, the electrochemical sensor may comprise a glucose sensor.
In addition, the electrochemical sensor can comprise an immunosensor.
The sample may comprise blood or whole blood.
The present invention also relates to a method of measuring a corrected analyte concentration in a sample which comprises: detecting a presence of the sample in an electrochemical sensor, the electrochemical sensor comprising two electrodes; reacting an analyte to cause a physical transformation of the analyte; determine a first concentration of analyte in the sample; and calculating a corrected analyte concentration based on the first analyte concentration and one or more correction factors. 5 The one or more correction factors can be calculated in view of at least one of the sample filling times, a physical property of the electrochemical sensor, a sample temperature and an electrochemical sensor temperature.
The physical property of the electrochemical sensor can be related to at least one of an age of the electrochemical sensor and a storage condition of the electrochemical sensor.
The method can also comprise the correction for glucose reaction kinetics.
In said method, the correction for glucose reaction kinetics may include calculating a second analyte concentration that depends on the first analyte concentration, so that the magnitude of the correction for glucose reaction kinetics is proportional to the magnitude of the first analyte concentration .
The method can achieve an accuracy standard of at least ± 10% so that at least 95% of a series of analyte concentration assessments yield an analyte concentration value that is accurate within a 10% range of an reference analyte measurement.
In addition, the step of reacting the analyte can generate an electroactive species that is measured as a current by the two electrodes.
The two electrodes can comprise an orientation facing the opposite side.
In addition, the two electrodes can comprise a forward orientation.
The present invention also relates to an electrochemical system that comprises an electrochemical sensor that includes electrical contacts configured to be compatible with a test meter, the electrochemical sensor comprising: a first electrode and a second electrode in one separate relationship, and a reagent; and the test meter that includes a processor configured to receive current data from the electrochemical sensor by applying voltages to the test strip, and con-
additionally figured to determine a corrected analyte concentration based on a calculated analyte concentration and one or more of a sample filling time, a physical property of the electrochemical sensor, a sample temperature, a temperature of the electrochemical sensor and glucose reaction kinetics.
In the said electrochemical system, the test meter can include a data store that contains an analyte concentration threshold and a plurality of thresholds related to one or more of the sample filling time, a physical property of the electrochemical sensor, a sample temperature, an electrochemical sensor temperature and the glucose reaction kinetics.
The system can achieve an accuracy standard of at least ± 10% for analyte concentrations above an analyte concentration threshold, so that at least 95% of a series of analyte concentration assessments yield a concentration value analyte which is accurate within ± 10% of a reference analyte measurement.
In addition, the system can achieve an accuracy standard of at least ± 10 mg / dl for analyte concentrations below the analyte concentration threshold, so that at least 95% of a series of analyte concentration assessments yield a analyte concentration value that is accurate within a range of about 10 mg / dl of a reference analyte measurement.
In said electrochemical system, the analyte concentration threshold can be approximately 75 mg / dl.
In addition, the electrochemical system may additionally comprise a heating element configured to heat at least a portion of the electrochemical sensor.
The electrochemical sensor may comprise a glycoside sensor.
In addition, the electrochemical sensor can comprise an immunosensor.
In said electrochemical system, at least one of the electrochemical sensor, the test meter and the processor can be configured to measure a sample temperature.
The analyte may comprise C-reactive protein.
In addition, the analyte can comprise glucose.
In said electrochemical system, the sample may comprise blood or whole blood.
The first and second electrodes can comprise an orientation facing the opposite side.
In addition, the first and second electrodes can comprise a forward orientation.
Although the invention has been described in terms of variations and particular illustrative figures, the person skilled in the art will recognize that the invention is not limited to the described variations or figures.
Furthermore, where the methods and steps described above indicate certain events that occur in a certain order, the person skilled in the art will recognize that the order of certain steps can be modified and that such changes are in accordance with the variations of the invention.
In addition, certain steps can be performed at the same time in a parallel process when possible, as well as carried out sequentially as described above.
Therefore, insofar as there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is also the aim that this patent covers these variations.
All publications and references cited herein are hereby expressly incorporated by reference in their entirety.

权利要求:
Claims (22)
[1]
1. Method of determining an analyte concentration in a sample, the method comprising: detecting a sample that includes an analyte introduced into an electrochemical sensor, the electrochemical sensor comprising two electrodes in a separate configuration; react the analyte to cause a physical transformation of the analyte between the two electrodes; measure current outputs at discrete intervals to derive a sample filling time at the sensor and a sensor capacitance with the sample; determining a first analyte concentration value from the current outputs; calculating a second analyte concentration value from the current outputs and the first analyte concentration value; correcting the second analyte concentration value for temperature purposes to provide a third analyte concentration value; correct the third analyte concentration value as a function of the sensor filling time to provide a fourth analyte concentration value; and correcting the fourth analyte concentration value as a function of capacitance to provide a final analyte concentration value.
[2]
A method according to claim 1, wherein the current outputs measured at discrete intervals comprise the first sum of current ir and a second sum of current il where: where i (t) comprises the absolute value of current measured at time t.
[3]
A method according to claim 2, wherein the step of determining the first analyte concentration value includes calculating an analyte concentration G1 with an equation of the form: wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; and zgr comprises about 2.25.
[4]
A method according to claim 2, wherein the step of calculating the second analyte concentration value includes calculating an analyte concentration G2 with an equation of the form: wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; AFO comprises about 2.88; zgr comprises about 2.25; and k comprises about 0.0000124.
[5]
A method according to claim 1, wherein the third analyte concentration value comprises a first temperature correction for the second analyte concentration value whenever an ambient temperature is greater than the first temperature threshold and a second temperature correction whenever the ambient temperature is less than or equal to the first temperature threshold.
[6]
6. Method, according to claim 1, in which the correction step of the third analyte concentration value as a function of the sensor filling time comprises calculating a filling time correction factor based on the filling time, in that: the fill time correction factor comprises about zero when the fill time is less than a first fill time threshold; the fill time correction factor is calculated based on the fill time when the fill time
[7]
is greater than the first fill time threshold and less than a second fill time threshold; and the fill time correction factor comprises a constant value when the fill time is greater than the second fill time threshold. 7. The method of claim 6, wherein the first fill time threshold comprises about 0.2 seconds and the second fill time threshold comprises about 0.4 seconds.
[8]
8. Method according to claim 7, wherein the fourth analyte concentration value is equal to the third analyte concentration value when the third analyte concentration value is less than about 100 mg / dl ; and the fourth analyte concentration value comprises a product of the third analyte concentration value, with a deviation for the fill time correction factor when the third analyte concentration value is greater than about 100 mg / dl .
[9]
9. The method of claim 1, wherein the final analyte concentration value is set equal to the fourth analyte concentration value when the fourth analyte concentration value is less than a first concentration threshold.
[10]
10. Method according to claim 1, wherein the final analyte concentration value comprises a product of a capacitance correction factor and the fourth analyte concentration value when the fourth analyte concentration value is greater that a first concentration threshold, and the capacitance correction factor for the final analyte concentration value is based on a capacitance measured when the capacitance is less than a first capacitance threshold and the capacitance correction factor is set to a maximum value when the calculated capacitance correction factor is greater than an established value.
[11]
11. Analyte measuring device comprising: a housing; a strip port connector mounted on the housing and configured
to receive an analyte test strip; and a microprocessor arranged in the housing, the microprocessor being connected to the strip port connectors, a power supply and a memory so that when a test strip is coupled to the strip port with a sample deposited in a test strip test chamber, the analyte is forced to react between the two electrodes and provide a first estimate of G1 analyte concentration based on the output current values measured over discrete intervals during a reaction of the analyte, a second estimate of G2 analyte concentration based on the output current values measured over discrete intervals during an analyte reaction, an analyte concentration value corrected by temperature G3 from the second concentration value analyte G2, an analyte concentration value corrected for sample filling time G4 from the third analyte concentration G3, and a fin concentration value al corrected by G5 test strip capacitance from the analyte concentration value corrected by sample filling time G4.
[12]
A device according to claim 11, wherein the discrete intervals comprise a first interval of about 3.9 seconds to about 4 seconds and a second interval of about 4.25 seconds to approximately 5 seconds, with the first and second intervals being measured from the moment a sample is deposited in the test chamber, so that the output current values measured over the first and second intervals comprise a first sum of current ir and a second sum of current il where i (t) comprises the absolute value of the current measured at time t.
[13]
Device according to claim 12, wherein the first analyte concentration value G1 comprises a derivation of the current values with an equation of the form: wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; and zgr comprises about 2.25.
[14]
Device according to claim 12, wherein the second analyte concentration value G2 comprises a derivation with an equation of the form: wherein p comprises about 0.5246; a comprises about 0.03422; i2 comprises an antioxidant-corrected current value; AFO comprises about 2.88; zgr comprises about 2.25; and k comprises about 0.0000124.
[15]
A device according to claim 13 or 14, in which i2 further comprises an equation of the form:  i (4.1) - 2i (1,1) + iss  i2 = ir    i (4, 1) + iss  where i (4,1) comprises an absolute value of the current during a third electrical potential; i (1,1) comprises an absolute value of the current during a second electrical potential; and iss comprises a steady state current.
[16]
A device according to claim 13 or 14, wherein iss comprises an equation of the form: wherein i (5) comprises an absolute value of the current during a third electrical potential; π comprises a constant; D comprises a diffusion coefficient of an oxide-reduction species and L comprises a distance between the two electrodes.
[17]
17. Device according to claim 11, in which the G3 temperature-corrected analyte concentration value is corrected by 5 a fill time correction factor based on a fill time, the correction time factor fill time comprises around zero when the fill time is less than a first fill time threshold and when the fill time is greater than the first fill time threshold and less than a second threshold fill time, the fill time correction factor is calculated based on the fill time and, when the fill time is greater than the second fill time threshold, the fill time correction factor comprises a constant value.
[18]
The device of claim 17, wherein the first fill time threshold comprises about 0.2 seconds and the second fill time threshold comprises about 0.4 seconds.
[19]
19. Device according to claim 17, in which the G3 temperature-corrected analyte concentration value comprises a first temperature correction for the second G2 analyte concentration value whenever an ambient temperature is greater than the first temperature threshold and a second temperature correction whenever the ambient temperature is less than or equal to the first temperature threshold.
[20]
20. Device according to claim 19, in which the fill time-corrected analyte concentration value G4 comprises the temperature-corrected concentration value G3 when the temperature-corrected concentration value G3 is less than about 100 mg / dl and the concentration value corrected by fill time G4 comprises a percentage increase in the third analyte concentration value in view of the fill time correction factor when the concentration value corrected by temperature G3 is higher than about 100 mg / dl.
[21]
21. Device according to claim 11, in which the final concentration value corrected by G5 test strip capacitance is set equal to the fourth analyte concentration value when the analyte concentration value corrected by sample filling time G4 is less than a first concentration threshold.
[22]
22. Device according to claim 11, wherein the final concentration value corrected by G5 test strip capacitance comprises a product of a capacitance correction factor and the time-corrected analyte concentration value of sample filling G4 when the analyte concentration value corrected by sample filling time G4 is greater than a first concentration threshold, and the capacitance correction factor for the final analyte concentration value G5 is based at a capacitance measured when the capacitance is less than a first capacitance threshold and the capacitance correction factor is set to a maximum value when the calculated capacitance correction factor is greater than an established value.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10371663B2|2019-08-06|Systems and methods for high accuracy analyte measurement

---

US9347910B2|2016-05-24|Systems and methods for improved stability of electrochemical sensors

---

JP2017203783A|2017-11-16|System, device and method for improving precision of biosensor by using charging time

---

EP2601520B1|2014-05-14|Method for improved accuracy for temperature correction of glucose results for control solution

---

JP6403653B2|2018-10-10|High accuracy analyte measurement system and method

---

JP6680702B2|2020-04-15|High accuracy analyte measurement system and method

---

JP6609001B2|2019-11-20|High accuracy analyte measurement system and method

---

AU2012200759B2|2014-07-24|Systems, devices and methods for improving accuracy of biosensors using fill time

同族专利:

---

公开号 | 公开日

---

AU2010366640A1|2013-07-25|

---

AU2010366640B2|2016-06-02|

---

US20170184542A1|2017-06-29|

---

JP2014504722A|2014-02-24|

---

RU2013135711A|2015-02-10|

---

CA2823180C|2018-10-23|

---

WO2012091728A1|2012-07-05|

---

US9632054B2|2017-04-25|

---

KR101749045B1|2017-06-20|

---

CN103718039B|2016-08-10|

---

CN103718039A|2014-04-09|

---

RU2564923C2|2015-10-10|

---

EP2659268A1|2013-11-06|

---

KR20130143634A|2013-12-31|

---

CA2823180A1|2012-07-05|

---

JP5837613B2|2015-12-24|

---

US10371663B2|2019-08-06|

---

US20130306493A1|2013-11-21|

---

EP2659268A4|2017-01-18|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US1455258A|1922-03-06|1923-05-15|Mcgreer Ray|Machine for cutting butter|

---

DE3719765A1|1987-06-13|1988-12-22|Agfa Gevaert Ag|COLOR DIFFUSION PROCESS|

---

US5719034A|1995-03-27|1998-02-17|Lifescan, Inc.|Chemical timer for a visual test strip|

---

RU2267120C2|2000-07-14|2005-12-27|Лайфскен, Инк.|Electrochemical mode of measuring of speed of chemical reactions|

---

CN1441902A|2000-07-14|2003-09-10|生命扫描有限公司|Electrochemical method for detecting chemical reaction speed|

---

US6391645B1|1997-05-12|2002-05-21|Bayer Corporation|Method and apparatus for correcting ambient temperature effect in biosensors|

---

US7494816B2|1997-12-22|2009-02-24|Roche Diagnostic Operations, Inc.|System and method for determining a temperature during analyte measurement|

---

WO1999060391A1|1998-05-20|1999-11-25|Arkray, Inc.|Method and apparatus for electrochemical measurement using statistical technique|

---

US6193873B1|1999-06-15|2001-02-27|Lifescan, Inc.|Sample detection to initiate timing of an electrochemical assay|

---

RU2278612C2|2000-07-14|2006-06-27|Лайфскен, Инк.|Immune sensor|

---

US6797150B2|2001-10-10|2004-09-28|Lifescan, Inc.|Determination of sample volume adequacy in biosensor devices|

---

US6872298B2|2001-11-20|2005-03-29|Lifescan, Inc.|Determination of sample volume adequacy in biosensor devices|

---

KR100475634B1|2001-12-24|2005-03-15|주식회사 아이센스|Biosensor equipped with sample introducing part which enables quick introduction of a small amount of sample|

---

US6945943B2|2002-05-01|2005-09-20|Lifescan, Inc.|Analyte concentration determination devices and methods of using the same|

---

DE60220288T2|2002-11-21|2008-01-17|Lifescan, Inc., Milpitas|Determining the accuracy of a sample volume in biosensors|

---

US7723099B2|2003-09-10|2010-05-25|Abbott Point Of Care Inc.|Immunoassay device with immuno-reference electrode|

---

EP1678490B1|2003-10-31|2009-07-01|Lifescan Scotland Ltd|A method of reducing interferences in an electrochemical sensor using two different applied potentials|

---

JP2008510154A|2004-08-16|2008-04-03|ノボ ノルディスク アクティーゼルスカブ|Multiphase biocompatible semipermeable membrane for biosensors|

---

KR100698961B1|2005-02-04|2007-03-26|주식회사 아이센스|Electrochemical Biosensor|

---

US7749371B2|2005-09-30|2010-07-06|Lifescan, Inc.|Method and apparatus for rapid electrochemical analysis|

---

JP2007121060A|2005-10-27|2007-05-17|Sumitomo Electric Ind Ltd|Sensor chip and sensor system|

---

US8163162B2|2006-03-31|2012-04-24|Lifescan, Inc.|Methods and apparatus for analyzing a sample in the presence of interferents|

---

EP2089531B1|2006-09-22|2019-07-10|Ascensia Diabetes Care Holdings AG|Biosensor system having enhanced stability and hematocrit performance|

---

EP2957908A1|2006-10-05|2015-12-23|Lifescan Scotland Limited|Methods for determining an analyte concentration using signal processing algorithms|

---

US7771583B2|2006-10-18|2010-08-10|Agamatrix, Inc.|Electrochemical determination of analytes|

---

US8080153B2|2007-05-31|2011-12-20|Abbott Diabetes Care Inc.|Analyte determination methods and devices|

---

US8551320B2|2008-06-09|2013-10-08|Lifescan, Inc.|System and method for measuring an analyte in a sample|

---

US8221994B2|2009-09-30|2012-07-17|Cilag Gmbh International|Adhesive composition for use in an immunosensor|

---

US8101065B2|2009-12-30|2012-01-24|Lifescan, Inc.|Systems, devices, and methods for improving accuracy of biosensors using fill time|

---

US8932445B2|2010-09-30|2015-01-13|Cilag Gmbh International|Systems and methods for improved stability of electrochemical sensors|

---

JP5837613B2|2010-12-31|2015-12-24|シラグ・ゲーエムベーハー・インターナショナルＣｉｌａｇ ＧＭＢＨ Ｉｎｔｅｒｎａｔｉｏｎａｌ|High accuracy analyte measurement system and method|

---

JP6403653B2|2015-11-05|2018-10-10|シラグ・ゲーエムベーハー・インターナショナルＣｉｌａｇ ＧＭＢＨ Ｉｎｔｅｒｎａｔｉｏｎａｌ|High accuracy analyte measurement system and method|JP5837613B2|2010-12-31|2015-12-24|シラグ・ゲーエムベーハー・インターナショナルＣｉｌａｇ ＧＭＢＨ Ｉｎｔｅｒｎａｔｉｏｎａｌ|High accuracy analyte measurement system and method|

---

MX360567B|2012-07-26|2018-11-08|Ascensia Diabetes Care Holdings Ag|Apparatus and methods for reducing electrical shock hazard from biosensor meters.|

---

EP2972268B1|2013-03-15|2017-05-24|Roche Diabetes Care GmbH|Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same|

---

EP2781919A1|2013-03-19|2014-09-24|Roche Diagniostics GmbH|Method / device for generating a corrected value of an analyte concentration in a sample of a body fluid|

---

KR101447970B1|2013-06-13|2014-10-13|명지대학교 산학협력단|Sensor strip for blood glucose monitoring, method of manufacturing the sensor strip, and monitoring device using the same|

---

US20150047976A1|2013-08-16|2015-02-19|Cilag Gmbh International|Analytical test strip having cantilevered contacts|

---

US9459231B2|2013-08-29|2016-10-04|Lifescan Scotland Limited|Method and system to determine erroneous measurement signals during a test measurement sequence|

---

US9243276B2|2013-08-29|2016-01-26|Lifescan Scotland Limited|Method and system to determine hematocrit-insensitive glucose values in a fluid sample|

---

US9442089B2|2013-12-23|2016-09-13|Lifescan Scotland Limited|Analyte meter test strip detection|

---

GB2531728A|2014-10-27|2016-05-04|Cilag Gmbh Int|Method for determining diffusion|

---

GB201419472D0|2014-10-31|2014-12-17|Inside Biometrics Ltd|Method of using and electrochemical device|

---

EP3224373A4|2014-11-25|2018-05-09|Polymer Technology Systems, Inc.|Systems and methods for hematocrit correction in analyte test strips|

---

US20160178559A1|2014-12-17|2016-06-23|Lifescan Scotland Limited|Universal strip port connector|

---

CN107110814A|2014-12-19|2017-08-29|豪夫迈·罗氏有限公司|Testing element for electrochemically detecting at least one analyte|

---

CN104750132B|2015-04-21|2017-03-15|三诺生物传感股份有限公司|A kind of test temperature bearing calibration, controller and test temperature correction system|

---

CN105445447B|2015-09-28|2018-03-27|腾讯科技（深圳）有限公司|Measuring method and device based on test paper|

---

WO2017069415A1|2015-10-20|2017-04-27|Lg Electronics Inc.|A sensor and method for manufacturing the sensor|

---

CN105606501B|2015-12-17|2018-11-02|小米科技有限责任公司|Dust concentration detecting method and device|

---

JP2019510207A|2016-01-28|2019-04-11|ロズウェル バイオテクノロジーズ，インコーポレイテッド|Super parallel DNA sequencing device|

---

CN109155354A|2016-02-09|2019-01-04|罗斯韦尔生物技术股份有限公司|DNA and gene order-checking of the electronics without label|

---

US10597767B2|2016-02-22|2020-03-24|Roswell Biotechnologies, Inc.|Nanoparticle fabrication|

---

CN105891297B|2016-05-09|2018-07-06|三诺生物传感股份有限公司|A kind of electrochemical measuring method|

---

US9829456B1|2016-07-26|2017-11-28|Roswell Biotechnologies, Inc.|Method of making a multi-electrode structure usable in molecular sensing devices|

---

CN106290530B|2016-08-31|2018-10-30|微泰医疗器械有限公司|It is a kind of can self-correction interference signal electrochemical analyte sensor-based system and method|

---

CN110431148A|2017-01-10|2019-11-08|罗斯威尔生命技术公司|Method and system for the storage of DNA data|

---

WO2018200687A1|2017-04-25|2018-11-01|Roswell Biotechnologies, Inc.|Enzymatic circuits for molecular sensors|

---

US10508296B2|2017-04-25|2019-12-17|Roswell Biotechnologies, Inc.|Enzymatic circuits for molecular sensors|

---

DE102017109227A1|2017-04-28|2018-10-31|Testo SE & Co. KGaA|Electrical measuring arrangement|

---

WO2018208505A1|2017-05-09|2018-11-15|Roswell Biotechnologies, Inc.|Binding probe circuits for molecular sensors|

---

WO2019046589A1|2017-08-30|2019-03-07|Roswell Biotechnologies, Inc.|Processive enzyme molecular electronic sensors for dna data storage|

---

EP3457121A1|2017-09-18|2019-03-20|Roche Diabetes Care GmbH|Electrochemical sensor and sensor system for detecting at least one analyte|

---

US11100404B2|2017-10-10|2021-08-24|Roswell Biotechnologies, Inc.|Methods, apparatus and systems for amplification-free DNA data storage|

---

KR102016393B1|2017-10-26|2019-09-10|오상헬스케어|Method and apparatus of measuring concentration of sample|

---

KR20190108306A|2018-03-14|2019-09-24|이승노|Anemia measurement system and method using hematocrit|

---

KR102352618B1|2019-12-31|2022-01-19|프리시젼바이오 주식회사|Test strip for immunoassay diagnosis using electric capacitance sensor|

法律状态:
2020-10-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2021-01-19| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-05-04| B11B| Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements|

---

2021-11-23| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

PCT/US2010/062629|WO2012091728A1|2010-12-31|2010-12-31|Systems and methods for high accuracy analyte measurement|

---